

Washington Mutual Investors Fund

Financial Statements and Other Information N-CSR Items 7-11

for the six months ended October 31, 2024

unaudited

Common sto	cks 96.80%	Shares	Value (000)
Energy	Canadian Natural Resources, Ltd.	34,959,725	\$ 1,189,330
4.41%	Cenovus Energy, Inc.	16,143,893	259,432
	Chevron Corp.	4,624,354	688,196
	ConocoPhillips	7,389,612	809,458
	EOG Resources, Inc. Exxon Mobil Corp.	16,311,754 17,687,141	1,989,382 2,065,504
	Halliburton Co.	21,475,170	2,085,504 595,721
	Schlumberger NV	7,239,368	290,082
	South Bow Corp. ¹	1,787,678	44,620
	TC Energy Corp.	8,938,391	415,725
			8,347,450
Materials	Air Products and Chemicals, Inc.	374,095	116,168
2.80%	Celanese Corp.	5,101,614	642,650
	Corteva, Inc.	13,834,019	842,769
	Freeport-McMoRan, Inc.	4,498,454	202,520
	H.B. Fuller Co. Linde PLC	1,612,937	118,035
	Linde PLC LyondellBasell Industries NV	4,082,436 2,593,633	1,862,203 225,257
	Mosaic Co.	5,993,648	160,390
	Nucor Corp.	1,992,519	282,619
	Rio Tinto PLC (ADR)	4,614,043	299,405
	Royal Gold, Inc.	469,839	68,625
	Wheaton Precious Metals Corp. ²	7,182,532	474,119
			5,294,760
Industrials	3M Co.	2,544,126	326,844
10.95%	ABB, Ltd. (ADR) ²	8,277,862	458,842
	BAE Systems PLC (ADR)	3,112,789	200,619
	Boeing Co. (The) ¹	5,197,558	776,047
	Broadridge Financial Solutions, Inc.	783,768	165,265
	Carrier Global Corp.	8,836,580	642,596
	Caterpillar, Inc.	4,878,249	1,835,197
	CSX Corp. Deere & Co.	19,292,848 1,211,365	649,011 490,227
	Delta Air Lines, Inc.	5,383,090	308,020
	Equifax, Inc.	1,327,805	351,895
	FedEx Corp.	1,218,710	333,744
	General Electric Co.	12,943,155	2,223,375
	HEICO Corp.	771,609	189,006
	Honeywell International, Inc.	792,967	163,098
	Ingersoll-Rand, Inc.	3,362,567	322,806
	Johnson Controls International PLC	9,175,870	693,237
	L3Harris Technologies, Inc.	4,070,129	1,007,235
	Lennox International, Inc.	150,894	90,924
	Lockheed Martin Corp.	310,835	169,731
	Northrop Grumman Corp.	3,989,577	2,030,775
	PACCAR, Inc.	5,073,423	529,057
	Parker-Hannifin Corp.	183,522	116,366
	Paychex, Inc.	8,718,321	1,214,724
	Republic Services, Inc.	1,181,526	233,942
	RTX Corp.	19,531,677	2,363,138
	Southwest Airlines Co. TransUnion	10,061,229 3 225 040	307,672
	Union Pacific Corp.	3,225,040 5 582 057	326,697 1,295,428
	United Parcel Service, Inc., Class B	5,582,057 1,121,791	1,295,428
	Veralto Corp.	2,340,659	239,192
	Waste Connections, Inc.	1,728,053	305,433
	Waste Management, Inc.	960,906	207,412
			20,717,942

Bineretionary Amazon.com, Inc. ¹ 2.4.01/02P 44/35 Chapted Mexican Gill, Inc. ¹ 2,190,250 122,15 DB. Hotton, Inc. 19,97725 337,46 Darden Restaurants, Inc. ² 9,599,021 123,163 General Motors Co. 25,154,04 12,64,04 Hotton Populate. 6,277,702 24,71,84 Home Depote Inc. 6,277,702 24,71,84 McDonald's Com. 11,86,84 323,94 McDonald's Com. 11,81,852 834,34 Royl Caribban Cruines, Iud. 21,142,85 13,143,46 Starbuck Corp. 11,142,87,43 14,142,97 Toctor Supply Co. 11,72,253 31,140 Vul Reserver, Inc. 12,005,476 11,453,793 Toctor Supply Co. 11,72,755 33,145 Vul Reserver, Inc. 11,453,793 11,453,793 Toctor Supply Co. 11,72,755 31,140 Vul Reserver, Inc. 11,453,794 11,452,755 Toctor Supply Co. 11,72,755 31,140 Vul Reserver, Inc. 11,456,77	Common stocks	(continued)	Shares	Value (000
243% Chipote Macian Grill, Inc. ¹ 2,192,200 122,15 DR. Hotoro, Inc. 1977,225 337,44 Darden Restaurants, Inc. ² 9,590,211 1,274,08 General Motoro Co. 6,277,709 2,471,84 Home Depct, Inc. 6,277,709 2,471,84 McDonald's Corp. 11,00,634 400,33 McDonald's Corp. 11,00,634 400,33 Schrock Corp. 11,00,634 400,33 Tractor Supply Co 11,22,800 435,944 Vill Resorts, Inc. 11,22,800 36,47 Vill Resorts, Inc. 11,22,800 31,49 Vill Resorts, Inc. 11,22,800 31,49 Vill Resorts, Inc. 11,22,800 31,49 Occore Cole Corp. 31,400,444 34,41 Corson Wholesale Corp. 31,400,444 34,41	Consumer			
D.B. (Horten, Inc. 19.97,925 337.44 Derden Restaurants, Inc. ¹ 9.590,021 15.21.63 General Motors Co. 25.155,404 1.27.68 Home Dept Inc. 26.277.09 24.71.64 Lennan Corp., Class A 1.06.048 181.54 Maintott International, Inc., Class A 1.06.048 181.54 Maintott International, Inc., Class A 1.06.048 133.84 Royal Cartibour Course, Ltd. 9.214.236 1.991.44 Song Group Corp. ADRP? 3.63.445 6.43.34 Tetals, Inc. ¹ 420.111 1.04.64 Starbuck Corp. 1.17.42.05 311.42.05 Tuccor Supply Co. 1.17.22.86 311.42.05 Tuccor Supply Co. 1.17.42.05 1.14.89.49 VIMI Brands, Inc. 20.095.62.6 1.14.89.49 Dunge Clobal SA 3.39.940 1.25.62 Consumer staples Abria Group, Inc. 3.13.99.540 1.12.52 Dunge Clobal SA 3.09.49.12.54 1.49.49.99 3.09.12.54 Consumer staples Constrof Samping Co., Inc. 3.19				447,552
Darden Restaurans, Inc ² 9,09,021 11,221,63 General Motors Co. 22,155,404 1,26,604 Home Depot, Inc. 10,26,014 11,81,83 Marriott International, Inc., Class A 11,806,33 333,43 McDonald's Corp. 13,81,852 834,63 Royal Carbon Corps. Ltd. 9,214,736 11,916,43 Sony Group Corp. (ADR)' 33,843 10,813,852 834,63 Royal Carbon Corps. Ltd. 9,214,736 11,42,03 11,42,03 Tards, Inc., 14,4011 114,96 11,42,03 11,42,03 Tards, Inc., 11,72,830 311,40 11,42,03 Tards, Inc., 12,060,076 11,835,904 314,19 Vail Resorts, Inc. 11,825,904 314,19 11,42,05 Consumer staples Altria Group, Inc. 11,816,19 11,816,19 Lift Wight American Tobacco FLC (ADR) 21,005,626 1,143,96 Dange Global SA 13,317,109 13,325,401 12,354 Constantion Brands, Inc., Class A 6,001,197 24,641,554 370,626	7.43%			
General Motors Co. 257,240 1.276,88 Home Dept, Inc. 6,227,709 2,471,48 Lannar Corp, Class A 1,781,85 450,33 Mirottol International, Inc., Class A 1,781,85 450,33 Marottol International, Inc., Class A 1,781,85 450,33 Royal Caribbean Cruises, Itcl. 9,214,736 1,901,46 Song Group, Corp., ADRP 3,631,445 64,33 Starbucks Corp. 1,1859,435 1,142,05 Tattoor Supply Co. 1,1859,439 1,142,05 Tattoor Supply Co. 1,1359,430 304,49 VUMI Brands, Inc. 12,060,964 1,1359,540 YUMI Brands, Inc. 21,005,626 1,143,56 Starbucks Corp. 21,005,626 1,143,56 Consumer staples Ahris Group, Inc. 21,005,626 1,143,56 K14% British Amorican Tobucco PLC (ADR) 20,574,565 719,404 Danner (ADR) 2,544,563 719,404 719,718 319,718 Constall Starb, Inc., Class A 6,661,479 1,643,577 22,084 <t< td=""><td></td><td></td><td></td><td></td></t<>				
Home Depot, Inc. 6.277,709 2.477,80 1.066,648 1815,55 Marriet Instrnational, Inc., Class A 1.731,85 450,33 McDonald's Corp. 1.088,434 32344 Royil Carboan Cruises, Ltd. 9.214,733 1.901,434 1.901,434 1.901,434 1.901,434 1.901,434 1.901,434 32344 Royil Carboan Cruises, Ltd. 9.214,733 1.901,443 1.901,434 1.901,443 1.901,443 1.901,443 1.901,443 1.901,443 1.901,443 1.901,443 1.901,443 1.901,443 1.901,443 1.901,443 1.901,443 1.901,443 1.901,443 1.901,443 1.901,443 1.901,443 1.901,443 1.901,443 3.901,991,553 1.901,443 3.901,991,553 1.901,443 3.901,991,553 1.901,443 3.901,991,553 1.901,443 3.901,991,553 1.901,443 3.901,991,553 1.901,443 3.901,991,553 1.901,443,433,993,593,593,593,593,593,593,593,593,5				
Lennar Corp., Class A Marritofi International, Inc., Class A Marchael International, Inc., Class A MIKE, Inc., Class B Royal Carloboan Craive, Ltd. Sorny Group, Corp., (ADR) ⁺ Statubods, Corp. 114205 Taula, Inc. 114205 Taula, Inc. 114205 Taula, Inc. 114205 Taula, Inc. 114205 114402 114402 11440 114205 114406 114407 114406 114407 114406 114407 114406 114407 11				
Mariott Ineerational, Inc., Class A 1,731,856 450,332 McDonald's Corp. 1,016,644 333,44 Royal Cambbean Cruises, Ltd. 9,214,726 81,403 Starbuck Corp. 11,089,419 1,142,05 Tesla, Inc. ¹ 3,653,445 643,33 Tark Corp. 11,089,419 1,142,05 Tark Corp. 11,089,419 1,142,05 Tark Corp. 1,335,944 304,19 Vull Brands, Inc. 1,335,944 304,19 VUll Brands, Inc. 1,335,944 304,19 VUll Brands, Inc. 1,335,940 112,666 Burge Global SA 20,574,555 1,148,98 Constellation Brands, Inc., Class A 6,061,459 1,408,98 Constellation Brands, Inc., Class A 6,061,459 1,408,98 Constellation Brands, Inc., Class A 6,061,459 1,408,98 Constellation Brands, Inc., Class A 7,191,464 445,577 Constellation Brands, Inc., Class A 7,191,464 445,577 Constellation Brands, Inc., Class A 7,191,464 445,577 Vin				
McDonald's Corp. 1,108,634 323,44 NIKE, Inc., Class B 10,815,82 334,43 Royal Carlibbean Cruises, Ltd. 9,214,736 44,20 Starbucks Corp. 11,469,439 11,426 Teils Inc.' 420,111 1045,62 Tarbucks Corp. 11,228,00 311,40 Vall Resorts, Inc. 12,260,92 11,235,00 Tractor Supply Co. 12,260,92 11,133,90 Vall Resorts, Inc. 12,005,426 11,43,96 Bunge Global SA 1,335,904 112,54 Consumer staples Altris Group, Inc. 11,25,83,93 Bunge Global SA 1,335,904 112,54 Consumer staples Altris Group, Inc. 14,405,33 Consumer staples Altris Group, Inc. 14,408,33 Consumer staples Altris Group, Inc. 12,408,402 Staff, Co., Inc. 12,348,402 33,157 Consumer staples Altris Group, Inc. 14,453,77 Staff, Staff, Forther Staff, Forthe				450,31
Reyal Caribbean Cruises, Ind. 9,214,736 1,921,4736 Sony Corpe, (ADR) ² 3,653,445 64.30 Starbucks Corp. 11,689,439 1,1426 Tiels, Inc. ¹ 420,111 104,96 UX Comparies, Inc. 1,235,904 633,544 Vail Resorts, Inc. 1,235,904 1,512,906 Consumer staples Atria Group, Inc. 1,235,904 1,125,80 Burge Global SA 1,339,540 112,54 Consumer staples Atria Group, Inc. 1,125,924 1,439,64 Burge Global SA 1,339,540 112,54 112,54 Conscole Co. 6,240,002 538,15 Constellation Brands, Inc., Class A 6,061,459 1,490,57 Constellation Brands, Inc., Class A 6,061,459 1,408,57 1,220,00 Dolar General Corp. 5,053,108 404,45 444,45 Heinbry Co. 1,172,66 422,49 7,181,76 Mordeley Liber Corp. 5,053,108 404,45 Heinbry Co. 1,144,402 3,987,065 5,982,21 Locar Corp. <td></td> <td>McDonald's Corp.</td> <td></td> <td>323,843</td>		McDonald's Corp.		323,843
Sory Group Corp. (ADB) ² 3,463,445 11,4205 Starbuck Corp. 11,469,439 11,4205 Tetela, Inc. ¹ 420,111 104,06 LIX Comparies, Inc. (The) 5,782,022 663,55 Tractor Supply Co. 1,123,8504 311,40 Vall Resons, Inc. 12,066,0954 1,581,91 YUMI Brands, Inc. 12,056,262 1,133,504 British American Tobacco PLC (ADR) 20,574,565 719,69 Burge Giobal SA 1,339,540 11,468,459 Burge Giobal Corp. 3,197,918 319,50 Coart-Cola Co. 3,197,918 319,50 Coart-Cola Co. 4,045,088 776,66 Costo Wholesale Corp. 5,61,619 4,040,22 Danone (ADR) ⁴ 2,649,854 379,620 Danone (ADR) ⁴ 2,649,853 379,620 Danone (ADR) ⁴ 2,649,854 379,620 Danone (ADR) ⁴ 2,649,853 379,620 Danone (ADR) ⁴ 2,649,853 379,620 Danone (ADR) ⁴ 7,197,766 422,49			10,818,582	834,43
Starbucks Corp. 11,489,439 11,42,05 Fiels, In1 420,111 104,66 TIX Companies, Inc. (The) 5,782,062 653,54 Tractor Supply Co. 11,722,850 311,40 Val Resorts, Inc. 12,060,964 15,81,91 Tubus Companies, Inc. 12,060,964 11,143,96 Starback Science PLC (ADR) 20,574,565 719,69 British American Tobacco PLC (ADR) 20,574,565 719,69 Burge Clobal SA 13,39,540 11,439,69 Consumer staples Altria Group, Inc. 31,97,918 319,520 Constellation Brands, Inc. Class A 6,061,459 14,060,31 Constellation Brands, Inc. Class A 6,061,459 14,080,88 Constellation Brands, Inc. Class A 6,061,459 14,080,88 Constellation Brands, Inc. Class A 6,061,459 14,080,88 Constellation Brands, Inc. Class A 7,191,764 442,022 Dalone (ADR) ⁶ 26,491,854 376,22 Dalone (ADR) ⁶ 15,577,114 12,429,57 Kimberly, Clark Corp. 4,445,048				1,901,46
Tesla, Inc. ¹ 104.8 TIX Companies, Inc. (The) 5,782.062 653.54 Toctor Supply Co. 1172.850 311.40 Vill Brands, Inc. 12,060,964 1581.91 VUMI Brands, Inc. 21,005.636 719.69 British American Tobacco PLC (ADR) 20,374.565 719.69 British American Tobacco PLC (ADR) 20,374.565 719.69 Consumer staples Ahria Group, Inc. 3,197.918 31950 Constellation Brands, Inc., Class A 6,061.459 1,480.84 379.62 Constellation Brands, Inc., Class A 6,061.459 1,480.84 379.62 Constellation Brands, Inc., Class A 6,061.459 1,408.08 370.62 Constellation Brands, Inc., Class A 6,061.459 1,408.08 370.62 Daller General Corp. 5,053.180 40.445 471.62 377.22.927 Kimberly-Clark Corp. 16.455.77 220.85 720.477 375.167 472.44 Protoct & Gamble Co. 4,244.619 731.37 359.60 579.277 151.457 Hearth Care <td></td> <td></td> <td></td> <td></td>				
TUX Companies, Inc. (The) 5,782,062 66334 Tractor Supply Co. 11,72,850 311,40 Vail Resorts, Inc. 12,060,944 15,81,91 Tux Companies, Inc. 12,005,626 1,143,96 Consumer staples Altria Group, Inc. 21,005,626 1,143,96 St14% British American Tobacco PLC (ADR) 20,574,555 719,90 Dunge Clobal SA 13,395,40 11,253 11,40 Consumer staples Constellation Brands, Inc, Class A 6,061,459 14,400 Constellation Brands, Inc, Class A 6,061,459 14,408 3762,002 Dalone (ADR) ² 26,491,854 3762,002 261,619 404,64 Horshey Co. 4,145,088 7762,002 14,485,088 7762,002 Dalone (ADR) ² 26,491,854 3762,002 14,485,088 7762,092 Mondelez International, Inc. 355,551,119 4,722,14 7191,766 4224,99 Mondelez International, Inc. 35,483,02 4,272,14 7191,766 4224,9507 Horster Abbit, Inc. 1				
Tractor Supply Co. 1.172,850 311,40 Vail Resorts, Inc. 1.383,590 304,19 YUMI Brands, Inc. 12,060,964 1.581,91 Technome staples Attria Group, Inc. 21,005,626 1.143,96 Burge Global SA 20,574,566 719,69 Consumer staples Burge Global SA 3197,911 319,500 Coca Coll Co. 32,200,022 538,15 Gonstellation Brands, Inc., Class A 6,061,157 1,490,95 Coca Coll Co. 32,200,022 538,15 Gonstellation Brands, Inc., Class A 6,061,157 1,490,95 Danone (ADR) ²¹ 26,491,854 379,62 1,453,088 736,08 Const Global Corp. 54,5167 1,464,577 20,080 736,08 Kairt Heirz Co, (The) 1,21,10,449 652,22 72,222,11,242,577 20,800 736,86 Kairt Heirz Co, (The) 1,91,0449 652,22 72,827 21,825,77 20,800 Kairt Heirz Co, (The) 1,91,91,0449 652,22 74,445,177 20,800 736,83 Kairt Heiriz Co, (The) <td></td> <td></td> <td></td> <td></td>				
Vail Resorts_Inc. 1,835,904 304,19 YUMI Brands, Inc. 12,060,964 1,181,97 Consumer staples Altria Group, Inc. 21,005,626 1,143,96 British American Tobacco PLC (ADR) 20,574,656 719,69 Bunge Global SA 1,339,940 112,54 Consumer staples 6,061,457 3197,071 3195,001 Corea-Cola Co. 8,240,022 538,15 Corea-Cola Co. 6,061,457 440,905 Consultation Brands, Inc., Class A 6,061,457 440,905 26,491,184 379,62 Dalar General Corp. 5,053,180 404,45 440,458 737,722,927 1,242,97 Kuning Dr Popper, Inc. 37,722,927 1,242,97 71,827,97 20,808 Koraft Heinz Co. (The) 19,510,449 652,82 Mondeler, International, Inc., Class A 7,191,76,4 42,92,97 Heinster, Gomp C. (Soma, Corp.) 51,439,003,75 1,449,507 51,37 Sysco Corp. 3,987,065 51,83 3,151,08 Abovit Laboratories 16,577,414 1,879,38 1,855,37 <td></td> <td></td> <td></td> <td></td>				
YUMI Brands, Inc. 12,060,964 1,581,91 Consumer staples Altria Group, Inc. 21,005,626 1,143,96 British American Tobacco PLC (ADR) 20,574,565 719,69 Bunge Global SA 1,339,540 112,364,94 Consumer staples 6,061,459 1142,66 Constellation Brands, Inc., Class A 6,061,459 1408,33 Constellation Brands, Inc., Class A 7,191,766 492,49 Hershey Co. 4,455,77 220,80 Kraft Heinz Co. (The) 19,510,449 652,82 Mondoleze International, Inc. 35,585,119 4,722,14 Procter & Gamble Co. 4,746,119 733,17 Sysco Corp. 5,486,339 31,510 Target Corp. 15,466,339 31,510 Abbott Laboratories 16,577,414				,
14,050,31 Consumer staples Altria Group, Inc. 21,005,626 1,143,98 British American Tobacco PLC (ADR) 20,574,565 719,69 Bunge Global SA 1,339,340 112,54 Corea-Cola Co. 8,240,022 538,15 Corea-Cola Co. 8,240,022 538,15 Corea-Cola Co. 8,240,022 538,15 Corto: Wholesale Corp. 501,119 490,95 Danone (ADR)? 26,491,854 376,62 Dollar General Corp. 5,053,180 404,45 Hershey Co. 4,145,088 736,082 Kumbery Clark Corp. 1,243,977 20,080 Kraft Heinz Co. (The) 19,510,449 652,82 Mondelez International, Inc 71,917,76 492,497 Proter K Gamble Co. 4,744,419 783,777 Reckitt Benckiser Group PLC (ADR) 4,249,507 51,373 Sysce Corp. 15,456,359 31,51,08 AstraZeneca PLC (ADR) 23,690,375 1,685,57 AstraZeneca PLC (ADR) 23,690,375 1,685,57				-
Consumer staples Altria Group, Inc. 21,005,626 5:14% British American Tobacco PLC (ADR) 20,574,555 719,69 Bunge Global SA 1,339,540 1125,55 Church & Dwight Co., Inc. 3,197,918 319,50 Coaca-Cola Co. 8,240,022 5381 Constellation Brands, Inc., Class A 6,061,459 1,408,31 Costco Wholesale Corp. 5,61,619 409,95 Dollar General Corp. 5,053,180 404,45 Hershey Co. 4,145,088 73,722,972 Kimberly-Clark Corp. 1,445,577 220,80 Kraft Heinz Co. (The) 1,951,0449 652,82 Mondelez International, Inc., Class A 7,191,766 49,297 Villay Morris International, Inc., Class A 7,191,766 49,249 Philip Morris International, Inc., Class A 7,191,766 598,21 Target Corp. 3,149,002 355,61 15,453,53 Sysco Corp. 5,144,902 353,55 15,43,324 Leath care Abbott Laboratories 1,6,577,414 1,879,33 Ast			,,	
\$14% British American Tobacco PLC (ADR) 20,574,565 779,59 Bunge Global SA 339,540 112,54 Church & Dwight Co., Inc. 3,197,918 315,50 Coas-Cola Co. 3,197,918 315,50 Coastellation Brands, Inc., Class A 6,061,459 1,408,31 Costco Wholesale Corp. 561,619 400,95 Dollar General Corp. 5,053,180 404,45 Hershey Co. 4,145,088 736,08 Keurig Dr Pepper, Inc. 37,722,927 1,242,97 Kimf Heinz Co. (The) 16,455,777 200,80 Kraft Heinz Co. 4,1744,619 783,17 Mondelez Intermational, Inc. 35,585,119 4,722,14 Procter & Gamble Co. 35,786,119 4,722,14 Procter & Gamble Co. 5,144,90 783,17 Sysco Corp. 3,987,055 598,21 Target Corp. 3,987,055 598,21 44,55% Abbyle, Inc. 1,645,6359 3,151,08 Antize A				
Bunge Global SA 1,339,540 112,54 Church & Dwight Co., Inc. 3,197,918 319,50 Coca-Cola Co. 8,240,022 538,15 Constellation Brands, Inc., Class A 6,061,459 1,408,31 Costo Wholesale Corp. 5,615,1619 490,95 Danone (ADR) ² 26,491,854 379,62 Dollar General Corp. 5,053,180 404,45 Hershey Co. 4,145,088 73,622,927 Kimberly-Clark Corp. 1,445,577 220,80 Kraft Heinz Co. (The) 1,9,510,449 652,82 Mondelez International, Inc., Class A 7,191,766 42,44 Philip Morris International, Inc. 35,585,119 4,722,14 Procter & Gamble Co. 4,744,619 733,73 Sysco Corp. 5,144,4002 385,61 Target Corp. 3,987,065 598,21 15,403,47 15,455,359 3,151,00 44,555% Abbott Laboratories 16,577,414 1,879,38 14,55% Abbott Laboratories 16,577,414 1,879,38 14,55%	Consumer staples			1,143,966
Church & Dwight Co., Inc. 3,179,7918 3192,002 Cocar-Cola Go. 8,240,002 538,15 Constellation Brands, Inc., Class A 6,061,459 1,408,31 Costor Wholesale Corp. 561,619 490,092 Dallar General Corp. 561,619 490,092 Dollar General Corp. 5,053,180 404,45 Hershey Co. 4,145,088 73,620 Keurig Dr Pepper, Inc. 37,722,927 1,242,97 Kimberly-Clark Corp. 16,455,577 220,80 Kraft Heinz Co. (The) 19,510,449 652,82 Mondelez International, Inc., Class A 7,191,766 492,49 Philip Morris International, Inc., Class A 7,191,766 492,49 Pototer & Gamble Co. 4,744,619 783,13 Sysco Corp. 5,144,902 385,61 Target Corp. 16,577,414 1.879,38 Abbvite, Inc. 2,347,334 731,20 AttaZeneca PLC (ADR) 23,690,375 1,665,359 Artazeneca PLC (ADR) 23,690,375 1,685,75 Dianater Corp. 4,45	8.14%			
Coa-Cola Co 8,240,022 538,15 Constellation Brands, Inc., Clas A 6,061,459 1,408,31 Costor Wholesale Corp. 561,619 440,959 Danone (ADR) ² 26,491,854 379,62 Dollar General Corp. 4,145,088 736,08 Hershey Co. 37,722,927 1,242,97 Kimberly-Clark Corp. 1,465,577 220,00 Kraft Heinz Co. (The) 1,9,510,449 652,82 Moondelz International, Inc., Class A 7,191,766 472,14 Procter & Gamble Co. 4,744,619 783,519 Philip Morris International, Inc. 35,585,119 4,722,14 Procter & Gamble Co. 4,744,902 385,61 Target Corp. 3,987,065 598,21 14,55% AbbVie, Inc. 15,456,359 3,151,08 AstraZeneca PLC (ADR) 2,347,354 751,52 Sistol-Myers Squibb Co. 6,450,211 359,72 CVS Health Corp. 2,467,351,91 1,359,72 CVS Health Corp. 4,957,041 1,217,74 Lis5% 64,862<				
Constellation Brands, Inc., Class A 6.061,459 1,408,31 Costco Wholesale Corp. 561,619 490,95 Danone (ADR) ¹ 26,491,854 379,62 Dollar General Corp. 5,053,180 404,45 Hershey Co. 4,145,088 736,080 Keurig Dr Pepper, Inc. 37,722,927 1,242,97 Kimberly-Clark Corp. 1,645,577 220,800 Kraft Heinz Co. (The) 19,510,449 652,82 Mondelez, International, Inc. 35,585,119 472,44 Procter & Gamble Co. 4,744,419 783,71 Sysco Corp. 5,144,902 385,61 Target Corp. 3,987,065 598,21 Target Corp. 5,144,902 385,61 Abbott Laboratories 16,577,414 1,879,38 Abbotte, Inc. 15,456,359 3151,06 Amgen, Inc. 2,347,354 751,52 AstraZeneca PLC (ADR) 2,447,351 1,85,75 AstraZeneca PLC (ADR) 4,646,862 684,46 Eli Lilly and Co. 6,450,211 339,75 <t< td=""><td></td><td>0</td><td></td><td>-</td></t<>		0		-
Costoo Wholesale Corp. 561,619 490,95 Danone (ADR) ² 26,491,854 379,65 Dollar General Corp. 5,053,180 404,45 Hershey Co. 4,145,088 736,08 Keurig Dr Pepper, Inc. 37,722,927 1,242,97 Kimberly-Clark Corp. 1,645,577 220,80 Kraft Heinz Co. (The) 1,9510,449 652,82 Mondelez International, Inc., Class A 7,191,766 492,49 Philip Morris International, Inc. 35,585,119 4,722,14 Procter & Gamble Co. 4,744,419 783,71 Sysco Corp. 5,144,90 2385,61 Target Corp. 5,144,90 2385,61 Target Corp. 5,144,90 2385,61 Target Corp. 5,144,90 23,893,75 Abbotic, Inc. 2,347,354 751,52 Agristol-Myers Squibb Co. 6,450,211 359,72 CVS Health Corp. 24,073,519 1,359,72 CVS Health Corp. 24,073,517 1,365,73 Bristol-Myers Squibb Co. 6,450,211 359,72 </td <td></td> <td></td> <td></td> <td></td>				
Danone (ADR) ² 26,491,854 379,25 Dollar General Corp. 5,053,180 404,45 Hershey Co. 4,145,088 736,08 Keurig Dr Pepper, Inc. 37,722,927 1,242,577 Kimberly-Clark Corp. 1,445,577 220,80 Kraft Heinz Co. (The) 19,510,449 652,82 Mondeler International, Inc., Class A 7,191,766 492,249 Philip Morris International, Inc., Class A 7,191,766 492,479 Procter & Gamble Co. 4,744,619 783,73 Sysco Corp. 5,144,902 385,61 Target Corp. 3,987,065 598,21 14,55% Abbott Laboratories 16,577,414 1,879,38 14,55% Abbotyle, Inc. 15,456,359 3,151,04 44,455% Abbotyle, Inc. 2,346,93,75 1,685,77 14,455% Abbotyle, Inc. 15,456,359 3,151,04 44,455% Abbotyle, Inc. 1,6,577,414 1,879,38 14,455% Abbotyle, Inc. 1,540,317 1,351,717 12,407,3151 2,				
Dollar General Corp. 5,053,180 404,45 Hershey Co. 4,145,088 736,08 Keurig Dr Pepper, Inc. 3,722,927 1,242,97 Kimberly-Clark Corp. 1,645,577 220,80 Kräft Heinz Co. (The) 1,9510,4449 652,82 Mondelez International, Inc., Class A 7,191,766 492,49 Philip Morris International, Inc. 35,585,119 4,722,14 Procter & Gamble Co. 4,744,4019 783,71 Reckitt Benckiser Group PLC (ADR) 4,249,507 51,33 Sysco Corp. 5,144,902 385,61 Target Corp. 3,987,065 598,21 15,450,359 3,151,08 4,455,73 Amgen, Inc. 2,347,354 751,23 AstraZeneca PLC (ADR) 2,347,354 751,23 AstraZeneca PLC (ADR) 2,349,037 1,685,73 AstraZeneca PLC (ADR) 2,349,037 1,51,493 CVS Health Corp. 4,957,041 1,217,74 Elevance Health, Inc. 1,868,682 684,40 Eli Lilly and Co. 6,248,220 51				
Hershey Co. 4,145,088 736,08 Keurig Dr Pepper, Inc. 37,722,927 1,242,97 Kimberly-Clark Corp. 16,455,77 220,80 Kraft Heinz Co. (The) 19,510,449 652,82 Mondelez International, Inc., Class A 71,91,766 492,49 Philip Morris International, Inc., Class A 35,585,119 4,722,14 Procter & Gamble Co. 4,744,619 783,71 Sysco Corp. 5,144,902 385,41 Target Corp. 3,987,065 598,21 Target Corp. 3,987,065 15,437 Abbott Laboratories 16,577,414 1,879,38 44.55% Abbott, Inc. 15,436,359 3,151,08 Amgen, Inc. 2,347,354 751,52 AstraZeneca PLC (ADR) 2,3690,375 1,685,57 Bristol-Myers Squibb Co. 6,450,211 359,72 CVS Health Corp. 24,073,519 1,217,74 Elevance Health, Inc. 1,686,82 684,46 Eli Lilly and Co. 6,248,220 5,184,39 Gilead Sciences, Inc. 23,78,2				404,45
Kimberly-Clark Corp. 1,645,577 220,80 Kraft Heinz Co. (The) 19,510,449 652,82 Mondelez International, Inc. 35,585,119 4,722,14 Procter & Gamble Co. 4,744,619 753,137 Reckitt Benckiser Group PLC (ADR) 4,249,507 51,337 Sysco Corp. 3,987,062 3987,062 Target Corp. 3,987,065 598,21 Istadam 15,445,002 385,61 Augen, Inc. 2,347,354 751,52 Abbott Laboratories 16,577,414 1,879,38 14.55% Abbotic, Inc. 2,347,354 751,52 Aristol-Myers Squibb Co. 6,450,211 359,71 CVS Health Corp. 24,073,519 1,59,194 Danher Corp. 24,073,519 1,59,197 Danher Corp. 24,073,519 1,59,197 Birstol-Myers Squibb Co. 6,488,822 518,439 Gilead Sciences, Inc. 1,237,78 337,577 Birden Corp. 2,138,653 341,488 Merck & Co., Inc. 6,540,695 669,24				736,085
Kraft Heinz Co. (The) 19,510,449 652,82 Mondelez International, Inc., Class A 7,191,766 492,49 Philip Morris International, Inc. 35,585,119 4,722,14 Procter & Gamble Co. 4,744,419 783,71 Reckitt Benckiser Group PLC (ADR) 4,249,507 51,37 Sysco Corp. 5,144,902 385,61 Target Corp. 3,987,065 598,21		Keurig Dr Pepper, Inc.	37,722,927	1,242,97 <i>°</i>
Mondelez International, Inc., Class A 7,191,766 492,49 Philip Morris International, Inc. 35,885,119 4,722,14 Procter & Gamble Co. 4,744,619 783,71 Reckitt Benckiser Group PLC (ADR) 4,249,507 51,37 Sysco Corp. 5,144,902 385,61 Target Corp. 3,987,065 598,21 4ealth care Abbott Laboratories 16,577,414 1,879,38 14.55% Abbott, Inc. 2,347,354 751,52 AstraZeneca PLC (ADR) 2,349,375 1,685,57 Bristol-Myers Squibb Co. 6,450,211 359,719 CVS Health Corp. 4,957,041 1,217,74 Elevance Health, Inc. 1,868,862 684,46 El illy and Co. 6,248,220 5184,39 Gilead Sciences, Inc. 1,217,778 337,852 Johnson & Johnson 2,138,653 341,88 Merck & Co, Inc. 2,2525,757 2,000,73 Humana, Inc. ¹ 237,829 34,282 Johnson & Johnson 2,138,653 341,88 Merck & Co, I		Kimberly-Clark Corp.		220,804
Philip Morris International, Inc. 35,585,119 4,742,11 Procter & Gamble Co. 4,744,619 783,71 Reckitt Benckiser Group PLC (ADR) 4,249,507 51,137 Sysco Corp. 5,144,902 385,61 Target Corp. 3,987,065 598,21 Istendard 15,403,47 15,403,47 Fealth care Abbott Laboratories 16,577,414 1,879,38 14.55% AbbVie, Inc. 15,456,359 3,151,08 Amgen, Inc. 2,347,355 3,515,08 ArtaZeneca PLC (ADR) 23,690,375 1,685,57 Bristol-Myers Squibb Co. 6,450,211 359,704 CVS Health Corp. 24,073,519 1,359,19 Danaher Corp. 4,957,014 1,217,74 Elevance Health, Inc. 1,686,862 684,46 Eli Lilly and Co. 6,248,220 5,184,39 Gilead Sciences, Inc. 2,257,57 2,000,73 Humana, Inc. 237,829 34,28 Johnson & Johnson 2,38,653 3,41,88 Merck & Co., Inc. 6,540,6				652,820
Procter & Gamble Co. 4,744,619 783,71 Reckit Benckiser Group PLC (ADR) 4,249,507 51,34,902 Sysce Corp. 5,144,902 3987,065 Target Corp. 3,987,065 598,21 15,403,47 15,403,47 15,403,47 tealth care Abbott Laboratories 16,577,414 1,879,38 Amgen, Inc. 2,347,354 751,52 AstraZeneca PLC (ADR) 23,690,375 1,685,57 Bristol-Myers Squibb Co. 6,450,211 359,72 CVS Health Corp. 24,073,519 1,359,19 Danaher Corp. 4,957,041 1,217,74 Elevance Health, Inc. 1,686,862 684,46 El Lilly and Co. 6,248,20 5,184,39 Gilead Sciences, Inc. 22,525,757 2,000,73 Humman, Inc. 1,310,778 337,49 Johnson & Johnson 2,138,653 341,88 Merck & Co, Inc. 6,540,695 6669,24 Novo Nordisk AS, Class B (ADR) 3,940,909 441,18 Prizer, Inc. 11,222,599 317,59<				
Reckitt Benckiser Group PLC (ADR) 4,249,507 51,37 Sysco Corp. 5,144,902 385,61 Target Corp. 3,987,065 598,21 Is.403,47 15,403,47 tealth care Abbott Laboratories 16,577,414 1,879,38 Amgen, Inc. 2,347,354 751,52 AstraZeneca PLC (ADR) 2,3690,375 1,685,57 Bristol-Myers Squibb Co. 6,450,211 359,79 CVS Health Corp. 24,073,519 1,359,19 Danaher Corp. 4,957,041 1,217,74 Elevance Health, Inc. 1,686,862 684,46 Eli Lilly and Co. 6,248,220 5,184,39 Gilead Sciences, Inc. 2,252,757 2,000,73 Humana, Inc. ¹ 237,829 34,28 Johnson & Johnson 2,138,653 341,88 Merck & Co., Inc. 6,540,695 669,24 Novo Nordisk AS, Class B (ADR) 3,940,909 441,18 Pfizer, Inc. 11,222,599 317,59 Regeneron Pharmaceuticals, Inc. ¹ 97,677 81,87 <t< td=""><td></td><td></td><td></td><td></td></t<>				
Sysco Corp. Target Corp. 5,144,902 385,61				
Target Corp. 3,987,065 598,21 15,403,47 15,403,47 Itealth care Abbott Laboratories 16,577,414 1,879,38 AbbVie, Inc. 15,456,359 3,151,08 Amgen, Inc. 2,347,354 751,52 AstraZeneca PLC (ADR) 23,690,375 1,685,57 Bristol-Myers Squibb Co. 6,450,211 359,72 CVS Health Corp. 24,073,519 1,359,72 Danaher Corp. 4,957,041 1,217,74 Elevance Health, Inc. 1,686,862 684,46 Eli Lilly and Co. 6,248,220 5,184,39 Gilead Sciences, Inc. 237,829 34,28 Johnson & Johnson 2,138,653 341,88 Merck & Co., Inc. 6,540,695 669,24 Novo Nordisk AS, Class B (ADR) 3,940,909 441,18 Pfizer, Inc. 11,222,599 317,59 Regeneron Pharmaceuticals, Inc. ¹ 97,677 81,87 UnitedHealth Group, Inc. 97,39,254 5,497,80 Vertex Pharmaceuticals, Inc. ¹ 2,936,678 1,397,80				
Health care Abbott Laboratories 16,577,414 1,879,38 14.55% AbbVie, Inc. 15,456,359 3,151,08 Amgen, Inc. 2,347,354 751,52 AstraZeneca PLC (ADR) 23,690,375 1,685,577 Bristol-Myers Squibb Co. 6,450,211 359,72 CVS Health Corp. 24,073,519 1,359,19 Danaher Corp. 4,957,041 1,217,74 Elevance Health, Inc. 1,686,862 684,46 Eli Lilly and Co. 6,248,220 5,184,39 Gilead Sciences, Inc. 22,525,757 2,000,73 Humana, Inc. 1,310,778 337,955 Illumina, Inc. ¹ 237,829 34,24 Johnson & Johnson 2,138,653 341,88 Merck & Co., Inc. 6,540,695 669,24 Novo Nordisk AS, Class B (ADR) 3,940,909 441,18 Pizer, Inc. 11,222,599 317,595 Regeneron Pharmaceuticals, Inc. ¹ 97,677 81,87 UnitedHealth Group, Inc. 97,677 81,87 UnitedHealth Group, Inc.				598,219
AbbVie, Inc. 15,456,359 3,151,08 Amgen, Inc. 2,347,354 751,52 AstraZeneca PLC (ADR) 23,690,375 1,685,57 Bristol-Myers Squibb Co. 6,450,211 359,72 CVS Health Corp. 24,073,519 1,359,19 Danaher Corp. 4,957,041 1,217,74 Elevance Health, Inc. 1,686,862 684,46 Eli Lilly and Co. 6,248,220 5,184,39 Gilead Sciences, Inc. 22,525,757 2,000,73 Humana, Inc. ¹ 237,829 34,28 Johnson & Johnson 2,138,653 341,88 Merck & Co., Inc. 6,540,695 669,24 Novo Nordisk AS, Class B (ADR) 3,940,909 441,18 Pfizer, Inc. 11,222,599 317,57 Regeneron Pharmaceuticals, Inc. ¹ 97,677 81,87 UnitedHealth Group, Inc. 9,739,254 5,497,80 Vertex Pharmaceuticals, Inc. ¹ 2,936,678 1,397,80 Zoetis, Inc., Class A 808,214 144,49				15,403,47
AbbVie, Inc. 15,456,359 3,151,08 Amgen, Inc. 2,347,354 751,52 AstraZeneca PLC (ADR) 23,690,375 1,685,57 Bristol-Myers Squibb Co. 6,450,211 359,72 CVS Health Corp. 24,073,519 1,359,19 Danaher Corp. 4,957,041 1,217,74 Elevance Health, Inc. 1,686,862 684,46 Eli Lilly and Co. 6,248,220 5,184,39 Gilead Sciences, Inc. 22,525,757 2,000,73 Humana, Inc. ¹ 237,829 34,28 Johnson & Johnson 2,138,653 341,88 Merck & Co., Inc. 6,540,695 669,24 Novo Nordisk AS, Class B (ADR) 3,940,909 441,18 Pfizer, Inc. 11,222,599 317,57 Regeneron Pharmaceuticals, Inc. ¹ 97,677 81,87 UnitedHealth Group, Inc. 9,739,254 5,497,80 Vertex Pharmaceuticals, Inc. ¹ 2,936,678 1,397,80 Zoetis, Inc., Class A 808,214 144,49			4/ 577 444	4 070 00
Amgen, Inc. 2,347,354 751,52 AstraZeneca PLC (ADR) 23,690,375 1,685,57 Bristol-Myers Squibb Co. 6,450,211 359,72 CVS Health Corp. 24,073,519 1,359,19 Danaher Corp. 4,957,041 1,217,74 Elevance Health, Inc. 1,686,862 684,46 Eli Lilly and Co. 6,248,220 5,184,39 Gilead Sciences, Inc. 1,310,778 337,95 Illumina, Inc. ¹ 237,829 34,28 Johnson & Johnson 2,138,653 341,88 Merck & Co., Inc. 6,540,695 669,24 Novo Nordisk AS, Class B (ADR) 3,940,909 441,18 Pfizer, Inc. 11,222,599 317,59 Regeneron Pharmaceuticals, Inc. ¹ 97,677 81,87 UnitedHealth Group, Inc. 97,677 81,87 Vertex Pharmaceuticals, Inc. ¹ 2,936,678 1,397,80 Zoetis, Inc., Class A 808,214 144,49				
AstraZeneca PLC (ADR) 23,690,375 1,685,57 Bristol-Myers Squibb Co. 6,450,211 359,72 CVS Health Corp. 24,073,519 1,359,19 Danaher Corp. 4,957,041 1,217,74 Elevance Health, Inc. 1,686,862 684,46 Eli Lilly and Co. 6,248,220 5,184,39 Gilead Sciences, Inc. 22,525,757 2,000,73 Humana, Inc. 1,310,778 337,95 Illumina, Inc. ¹ 237,829 34,28 Johnson & Johnson 2,138,653 341,88 Merck & Co., Inc. 6,540,695 669,24 Novo Nordisk AS, Class B (ADR) 3,940,909 441,18 Pfizer, Inc. 11,222,599 317,59 Regeneron Pharmaceuticals, Inc. ¹ 97,677 81,87 UnitedHealth Group, Inc. 97,39,254 5,497,80 Vertex Pharmaceuticals, Inc. ¹ 2,936,678 1,397,80 Zoetis, Inc., Class A 808,214 144,49	17.3370			
Bristol-Myers Squibb Co. 6,450,211 359,72 CVS Health Corp. 24,073,519 1,359,19 Danaher Corp. 4,957,041 1,217,74 Elevance Health, Inc. 1,686,862 684,46 Eli Lilly and Co. 6,248,220 5,184,39 Gilead Sciences, Inc. 22,525,757 2,000,73 Humana, Inc. 1,310,778 337,95 Illumina, Inc. ¹ 237,829 34,28 Johnson & Johnson 2,138,653 341,88 Merck & Co., Inc. 6,540,695 669,24 Novo Nordisk AS, Class B (ADR) 3,940,909 441,18 Pfizer, Inc. 11,222,599 317,59 Regeneron Pharmaceuticals, Inc. ¹ 97,677 81,87 UnitedHealth Group, Inc. 9,739,254 5,497,80 Vertex Pharmaceuticals, Inc. ¹ 2,936,678 1,397,80 Zoetis, Inc., Class A 808,214 144,49				
CVS Health Corp. 24,073,519 1,359,19 Danaher Corp. 4,957,041 1,217,74 Elevance Health, Inc. 1,686,862 684,46 Eli Lilly and Co. 6,248,220 5,184,39 Gilead Sciences, Inc. 22,525,757 2,000,73 Humana, Inc. 1,310,778 337,95 Illumina, Inc. ¹ 237,829 34,28 Johnson & Johnson 2,138,653 341,88 Merck & Co., Inc. 6,540,695 669,24 Novo Nordisk AS, Class B (ADR) 3,940,909 441,18 Pfizer, Inc. 11,222,599 317,59 Regeneron Pharmaceuticals, Inc. ¹ 97,677 81,87 UnitedHealth Group, Inc. 9,739,254 5,497,80 Vertex Pharmaceuticals, Inc. ¹ 2,936,678 1,397,80 Zoetis, Inc., Class A 808,214 144,49				
Danaher Corp. 4,957,041 1,217,74 Elevance Health, Inc. 1,686,862 684,46 Eli Lilly and Co. 6,248,220 5,184,39 Gilead Sciences, Inc. 22,525,757 2,000,73 Humana, Inc. 1,310,778 337,95 Illumina, Inc. ¹ 237,829 34,28 Johnson & Johnson 2,138,653 341,88 Merck & Co., Inc. 6,540,695 669,24 Novo Nordisk AS, Class B (ADR) 3,940,909 441,18 Pfizer, Inc. 11,222,599 317,59 Regeneron Pharmaceuticals, Inc. ¹ 97,677 81,87 UnitedHealth Group, Inc. 9,739,254 5,497,80 Vertex Pharmaceuticals, Inc. ¹ 2,936,678 1,397,80 Zoetis, Inc., Class A 808,214 144,49				
Eli Lilly and Co. 6,248,220 5,184,39 Gilead Sciences, Inc. 22,525,757 2,000,73 Humana, Inc. 1,310,778 337,95 Illumina, Inc. ¹ 237,829 34,28 Johnson & Johnson 2,138,653 341,88 Merck & Co., Inc. 6,540,695 669,24 Novo Nordisk AS, Class B (ADR) 3,940,909 441,18 Pfizer, Inc. 11,222,599 317,59 Regeneron Pharmaceuticals, Inc. ¹ 97,677 81,87 UnitedHealth Group, Inc. 9,739,254 5,497,80 Vertex Pharmaceuticals, Inc. ¹ 2,936,678 1,397,80 Zoetis, Inc., Class A 808,214 144,49				1,217,74
Gilead Sciences, Inc. 22,525,757 2,000,73 Humana, Inc. 1,310,778 337,95 Illumina, Inc. ¹ 237,829 34,28 Johnson & Johnson 2,138,653 341,88 Merck & Co., Inc. 6,540,695 669,24 Novo Nordisk AS, Class B (ADR) 3,940,909 441,18 Pfizer, Inc. 11,222,599 317,59 Regeneron Pharmaceuticals, Inc. ¹ 97,677 81,87 UnitedHealth Group, Inc. 9,739,254 5,497,80 Vertex Pharmaceuticals, Inc. ¹ 2,936,678 1,397,80 Zoetis, Inc., Class A 808,214 144,49		Elevance Health, Inc.	1,686,862	684,46
Humana, Inc. 1,310,778 337,955 Illumina, Inc. ¹ 237,829 34,28 Johnson & Johnson 2,138,653 341,88 Merck & Co., Inc. 6,540,695 669,24 Novo Nordisk AS, Class B (ADR) 3,940,909 441,18 Pfizer, Inc. 11,222,599 317,59 Regeneron Pharmaceuticals, Inc. ¹ 97,677 81,87 UnitedHealth Group, Inc. 9,739,254 5,497,80 Vertex Pharmaceuticals, Inc. ¹ 2,936,678 1,397,80 Zoetis, Inc., Class A 808,214 144,49				5,184,39
Illumina, Inc. ¹ 237,829 34,28 Johnson & Johnson 2,138,653 341,88 Merck & Co., Inc. 6,540,695 669,24 Novo Nordisk AS, Class B (ADR) 3,940,909 441,18 Pfizer, Inc. 11,222,599 317,59 Regeneron Pharmaceuticals, Inc. ¹ 97,677 81,87 UnitedHealth Group, Inc. 9,739,254 5,497,80 Vertex Pharmaceuticals, Inc. ¹ 2,936,678 1,397,80 Zoetis, Inc., Class A 808,214 144,49				2,000,73
Johnson & Johnson 2,138,653 341,88 Merck & Co., Inc. 6,540,695 669,24 Novo Nordisk AS, Class B (ADR) 3,940,909 441,18 Pfizer, Inc. 11,222,599 317,59 Regeneron Pharmaceuticals, Inc. ¹ 97,677 81,87 UnitedHealth Group, Inc. 9,739,254 5,497,80 Vertex Pharmaceuticals, Inc. ¹ 2,936,678 1,397,80 Zoetis, Inc., Class A 808,214 144,49				337,95
Merck & Co., Inc. 6,540,695 669,24 Novo Nordisk AS, Class B (ADR) 3,940,909 441,18 Pfizer, Inc. 11,222,599 317,59 Regeneron Pharmaceuticals, Inc. ¹ 97,677 81,87 UnitedHealth Group, Inc. 9,739,254 5,497,80 Vertex Pharmaceuticals, Inc. ¹ 2,936,678 1,397,80 Zoetis, Inc., Class A 808,214 144,49				
Novo Nordisk AS, Class B (ADR) 3,940,909 441,18 Pfizer, Inc. 11,222,599 317,59 Regeneron Pharmaceuticals, Inc. ¹ 97,677 81,87 UnitedHealth Group, Inc. 9,739,254 5,497,80 Vertex Pharmaceuticals, Inc. ¹ 2,936,678 1,397,80 Zoetis, Inc., Class A 808,214 144,49				
Pfizer, Inc. 11,222,599 317,59 Regeneron Pharmaceuticals, Inc. ¹ 97,677 81,87 United Health Group, Inc. 9,739,254 5,497,80 Vertex Pharmaceuticals, Inc. ¹ 2,936,678 1,397,80 Zoetis, Inc., Class A 808,214 144,49				
Regeneron Pharmaceuticals, Inc. ¹ 97,677 81,87 United Health Group, Inc. 9,739,254 5,497,80 Vertex Pharmaceuticals, Inc. ¹ 2,936,678 1,397,80 Zoetis, Inc., Class A 808,214 144,49				
UnitedHealth Group, Inc. 9,739,254 5,497,80 Vertex Pharmaceuticals, Inc. ¹ 2,936,678 1,397,80 Zoetis, Inc., Class A 808,214 144,49		•		
Vertex Pharmaceuticals, Inc. ¹ 2,936,678 1,397,80 Zoetis, Inc., Class A 808,214 144,49				
Zoetis, Inc., Class A 808,214 144,49				
				144,492
				27,537,95

Common stock	S (continued)	Shares	Valu (000
Financials	American Express Co.	1,416,991	\$ 382,70
16.99%	Aon PLC, Class A	1,730,978	635,04
	Apollo Asset Management, Inc.	7,092,861	1,016,12
	Arthur J. Gallagher & Co.	3,762,337	1,057,96
	Bank of America Corp.	12,167,268	508,83
	BlackRock, Inc. Blackstone, Inc.	2,360,464 10,542,489	2,315,68 1,768,50
	Brookfield Asset Management, Ltd., Class A	8,341,072	442,41
	Canadian Imperial Bank of Commerce ²	4,935,470	308,76
	Capital One Financial Corp.	3,606,761	587,14
	Carlyle Group, Inc. (The)	5,260,283	263,17
	Chubb, Ltd.	5,977,041	1,688,15
	Citizens Financial Group, Inc.	18,424,930	776,05
	CME Group, Inc., Class A	2,889,466	651,17
	Discover Financial Services	7,558,634	1,121,92
	Fifth Third Bancorp	3,004,436	131,23
	Goldman Sachs Group, Inc.	646,068	334,52
	Intercontinental Exchange, Inc.	3,242,799	505,45
	JPMorgan Chase & Co. KKR & Co., Inc.	13,684,503 12,533,272	3,036,86
	Marsh & McLennan Companies, Inc.	19,757,546	1,732,60 4,311,88
	Marsh & McLenhan Companies, Inc. Mastercard, Inc., Class A	3,780,562	1,888,73
	Morgan Stanley	8,864,253	1,030,46
	MSCI, Inc.	174,834	99,86
	Nasdaq, Inc.	4,020,878	297,22
	PNC Financial Services Group, Inc.	1,175,817	221,37
	S&P Global, Inc.	1,927,676	925,97
	Truist Financial Corp.	14,775,383	636,08
	Visa, Inc., Class A	7,564,400	2,192,54
	Wells Fargo & Co.	19,805,387	1,285,76
			32,154,25
Information	Accenture PLC, Class A	1,386,273	478,01
technology	Apple, Inc.	18,598,890	4,201,67
19.97%	Applied Materials, Inc.	6,390,539	1,160,39
	ASM International NV (ADR)	466,887	260,83
	ASML Holding NV (ADR)	2,110,831	1,419,63
	Broadcom, Inc.	69,937,340	11,873,26
	Cadence Design Systems, Inc. ¹	691,589	190,96
	Intel Corp.	11,590,730	249,43
	KLA Corp. Microsoft Corp.	869,621 24,826,990	579,36 10,088,44
	Microsoft Corp. Motorola Solutions, Inc.	24,828,770 2,658,926	1,194,78
	NetApp, Inc.	1,594,318	183,84
	NVIDIA Corp.	13,358,758	1,773,50
	Oracle Corp.	5,897,355	989,81
	Salesforce, Inc.	1,289,634	375,76
	SAP SE (ADR) ²	7,766,717	1,814,61
	Synopsys, Inc. ¹	554,785	284,94
	Texas Instruments, Inc.	3,312,266	672,92
			37,792,22
Communication	Alphabet Inc. Class A	/ 007 / / 7	1 105 / /
	Alphabet, Inc., Class A	6,987,667 12 395 139	
services	Alphabet, Inc., Class C	12,395,139	2,140,51
services	Alphabet, Inc., Class C AT&T, Inc.	12,395,139 2,584,647	2,140,51 58,25
services	Alphabet, Inc., Class C AT&T, Inc. Comcast Corp., Class A	12,395,139 2,584,647 63,882,387	2,140,51 58,25 2,789,74
services	Alphabet, Inc., Class C AT&T, Inc.	12,395,139 2,584,647 63,882,387 3,790,388	2,140,51 58,25 2,789,74 114,50
services	Alphabet, Inc., Class C AT&T, Inc. Comcast Corp., Class A Deutsche Telekom AG (ADR) ²	12,395,139 2,584,647 63,882,387	2,140,51 58,25 2,789,74 114,50 309,64
services	Alphabet, Inc., Class C AT&T, Inc. Comcast Corp., Class A Deutsche Telekom AG (ADR) ² Electronic Arts, Inc.	12,395,139 2,584,647 63,882,387 3,790,388 2,052,672	2,140,51 58,25 2,789,74 114,50 309,64 1,924,64
Communication services 5.02%	Alphabet, Inc., Class C AT&T, Inc. Comcast Corp., Class A Deutsche Telekom AG (ADR) ² Electronic Arts, Inc. Meta Platforms, Inc., Class A	12,395,139 2,584,647 63,882,387 3,790,388 2,052,672 3,390,970	1,195,66 2,140,51 58,25 2,789,74 114,50 309,64 1,924,64 290,33 678,78

Common sto	cks (continued)	Shares	Value (000)
Utilities 3.73%	CenterPoint Energy, Inc. Constellation Energy Corp. Entergy Corp. FirstEnergy Corp. NextEra Energy, Inc. Public Service Enterprise Group, Inc. Sempra Southern Co. (The)	9,534,757 7,984,885 2,031,552 23,653,431 2,137,276 4,250,000 17,797,468 14,626,223	\$ 281,561 2,099,705 314,444 989,423 169,379 379,993 1,483,775 1,331,425 7,049,705
Real estate 2.81%	American Tower Corp. REIT Equinix, Inc. REIT Extra Space Storage, Inc. REIT Mid-America Apartment Communities, Inc. REIT Prologis, Inc. REIT Public Storage REIT Welltower, Inc. REIT	2,098,900 482,685 7,872,276 3,237,142 4,326,156 791,547 14,188,512	448,199 438,317 1,285,543 489,909 488,596 260,466 1,913,746 5,324,776
	Total common stocks (cost: \$103,017,203,000)		183,174,949
Convertible s	tocks 0.20%		
Industrials 0.16%	Boeing Co., Series A, convertible preferred depositary shares, 6.00% 10/15/2027	5,811,500	312,252
Financials 0.04%	Apollo Global Management, Inc., Class A, cumulative convertible preferred shares, 6.75% 7/31/2026	906,506	69,230
	Total convertible stocks (cost: \$335,900,000)		381,482
Short-term se	curities 3.14%		
Money market i	nvestments 3.01%		
	Capital Group Central Cash Fund 4.87% ^{3,4}	56,926,986	5,692,699
Money market i	nvestments purchased with collateral from securities on loan 0.13%		
	Capital Group Central Cash Fund 4.87% ^{3,4,5}	934,650	93,465
	 Invesco Short-Term Investments Trust - Government & Agency Portfolio, Institutional Class 4.77%^{4,5} BlackRock Liquidity Funds - FedFund, Institutional Shares 4.76%^{4,5} Dreyfus Treasury Obligations Cash Management, Institutional Shares 4.72%^{4,5} Fidelity Investments Money Market Government Portfolio, Class I 4.70%^{4,5} Goldman Sachs Financial Square Government Fund, Institutional Shares 4.70%^{4,5} Morgan Stanley Institutional Liquidity Funds - Government Portfolio, 	38,864,220 16,400,000 16,400,000 16,400,000 16,400,000	38,865 16,400 16,400 16,400 16,400
	Institutional Class 4.78% ^{4,5}	16,400,000	16,400
		16,083,052	16,083
	State Street Institutional U.S. Government Money Market Fund, Premier Class 4.82% ^{4,5}	10,003,032	
		12,000,000	12,000
	Premier Class 4.82% ^{4,5} RBC Funds Trust - U.S. Government Money Market Fund,		
	Premier Class 4.82% ^{4,5} RBC Funds Trust - U.S. Government Money Market Fund,		242,413
	Premier Class 4.82% ^{4,5} RBC Funds Trust - U.S. Government Money Market Fund, RBC Institutional Class 1 4.77% ^{4,5}		12,000 242,413 5,935,112 189,491,543 (268,326

Investments in affiliates³

	Value at 5/1/2024 (000)	Additions (000)	Reductions (000)	Net realized gain (loss) (000)	Net unrealized appreciation (depreciation) (000)	Value at 10/31/2024 (000)	Dividend or interest income (000)
Common stocks 0.80%							
Materials 0.00%							
Celanese Corp. ⁶	\$1,193,729	\$ –	\$ 337,492	\$(16,246)	\$(197,341)	\$ -	\$ 9,009
Consumer discretionary 0.80%							
Darden Restaurants, Inc.	1,217,193	226,493	417	269	78,096	1,521,634	24,417
YUM! Brands, Inc. ⁶	2,194,316	1,253	464,394	(12,181)	(137,078)	-	20,813
						1,521,634	
Total common stocks						1,521,634	
Short-term securities 3.06%							
Money market investments 3.01%							
Capital Group Central Cash Fund 4.87% ⁴	6,398,719	8,649,566	9,355,563	235	(258)	5,692,699	171,548
Money market investments purchased with collateral from securities on Ioan 0.05%							
Capital Group Central Cash Fund 4.87% ^{4,5}	659	92,806 ⁷				93,465	_8
Total short-term securities						5,786,164	
Total 3.86%				\$(27,923)	\$(256,581)	\$7,307,798	\$225,787

¹Security did not produce income during the last 12 months.

²All or a portion of this security was on Ioan. The total value of all such securities was \$262,170,000, which represented .14% of the net assets of the fund. Refer to Note 5 for more information on securities lending.

³Affiliate of the fund or part of the same "group of investment companies" as the fund, as defined under the Investment Company Act of 1940, as amended. ⁴Rate represents the seven-day yield at 10/31/2024.

⁵Security purchased with cash collateral from securities on loan. Refer to Note 5 for more information on securities lending.

⁶Affiliated issuer during the reporting period but no longer an affiliate at 10/31/2024. Refer to the investment portfolio for the security value at 10/31/2024. ⁷Represents net activity. Refer to Note 5 for more information on securities lending.

⁸Dividend income is included with securities lending income in the fund's statement of operations and is not shown in this table.

Key to abbreviation(s)

ADR = American Depositary Receipts

REIT = Real Estate Investment Trust

Financial statements

Statement of assets and liabilities at October 31, 2024

unaudited

(dollars in thousands)

Assets:		
Investment securities, at value (includes \$262,170 of		
investment securities on loan):		
Unaffiliated issuers (cost: \$102,426,883)	\$182,183,745	
Affiliated issuers (cost: \$6,861,358)	7,307,798	\$189,491,543
Cash		418
Cash denominated in currencies other than U.S. dollars (cost: \$5,257)		5,257
Receivables for:		,
Sales of investments	204,352	
Sales of fund's shares	127,968	
Dividends	210,511	
Securities lending income	63	
Other	3	542,897
		190,040,115
Liabilities:		170,040,113
Collateral for securities on loan		242,413
Payables for:		212,110
Purchases of investments	368,722	
Repurchases of fund's shares	121,931	
Investment advisory services	36,325	
Services provided by related parties	28,207	
Board members' deferred compensation	18,429	
Other	871	574,485
Not exects at October 21, 2024		¢100 000 017
Net assets at October 31, 2024		\$189,223,217
Net assets consist of:		
Capital paid in on shares of beneficial interest		\$100,981,306
Total distributable earnings (accumulated loss)		88,241,911
Net assets at October 31, 2024		\$189,223,217

Statement of assets and liabilities at October 31, 2024 (continued)

unaudited

(dollars and shares in thousands, except per-share amounts)

Shares of beneficial interest issued and outstanding (no stated par value) – unlimited shares authorized (2,976,492 total shares outstanding)

	Net assets	Shares outstanding	Net asset value per share
Class A	\$87,461,875	1,374,726	\$63.62
Class C	1,390,282	22,279	62.40
Class T	15	_*	63.61
Class F-1	2,286,409	36,135	63.27
Class F-2	35,014,803	551,127	63.53
Class F-3	11,230,991	176,636	63.58
Class 529-A	3,498,855	55,182	63.41
Class 529-C	75,965	1,207	62.94
Class 529-E	112,268	1,786	62.86
Class 529-T	25	_*	63.61
Class 529-F-1	18	_*	63.14
Class 529-F-2	438,398	6,892	63.61
Class 529-F-3	111	2	63.61
Class R-1	67,105	1,071	62.63
Class R-2	778,545	12,510	62.23
Class R-2E	118,578	1,877	63.18
Class R-3	1,729,690	27,536	62.82
Class R-4	2,652,049	42,015	63.12
Class R-5E	557,063	8,776	63.47
Class R-5	662,692	10,422	63.59
Class R-6	41,147,480	646,313	63.66

*Amount less than one thousand.

Statement of operations for the six months ended October 31, 2024

unaudited

	(dollars in thousands)
¢ 4 074 440	
\$ 1,871,119	
	¢ 4 070 000
820	\$ 1,873,299
163	425,777
	1,447,522
35,981	
(200)	7,593,785
11,964,091	
(256,581)	
10	11,707,520
	19,301,305
	\$20,748,827
	11,964,091 (256,581)

*Additional information related to class-specific fees and expenses is included in the notes to financial statements.

Financial statements (continued)

Statements of changes in net assets

		(dollars in thousands)
	Six months ended October 31, 2024*	Year ended April 30, 2024
Operations:		
Net investment income	\$ 1,447,522	\$ 2,934,207
Net realized gain (loss)	7,593,785	12,179,738
Net unrealized appreciation (depreciation)	11,707,520	13,891,146
Net increase (decrease) in net assets resulting from operations	20,748,827	29,005,091
Distributions paid to shareholders	(9,333,812)	(10,257,462)
Net capital share transactions	3,871,852	1,554,663
Total increase (decrease) in net assets	15,286,867	20,302,292
Net assets:		
Beginning of period	173,936,350	153,634,058
End of period	\$189,223,217	\$173,936,350

*Unaudited.

Notes to financial statements

1. Organization

Washington Mutual Investors Fund (the "fund") is registered under the Investment Company Act of 1940, as amended (the "1940 Act"), as an open-end, diversified management investment company. The fund's investment objective is to produce income and to provide an opportunity for growth of principal consistent with sound common stock investing.

The fund has 21 share classes consisting of six retail share classes (Classes A, C, T, F-1, F-2 and F-3), seven 529 college savings plan share classes (Classes 529-A, 529-C, 529-E, 529-T, 529-F-1, 529-F-2 and 529-F-3) and eight retirement plan share classes (Classes R-1, R-2, R-2E, R-3, R-4, R-5E, R-5 and R-6). The 529 college savings plan share classes can be used to save for college education. The retirement plan share classes are generally offered only through eligible employer-sponsored retirement plans. The fund's share classes are described further in the following table:

Share class	Initial sales charge	Contingent deferred sales charge upon redemption	Conversion feature
Classes A and 529-A	Up to 5.75% for Class A; up to 3.50% for Class 529-A	None (except 1.00% for certain redemptions within 18 months of purchase without an initial sales charge)	None
Classes C and 529-C	None	1.00% for redemptions within one year of purchase	Class C converts to Class A after eight years and Class 529-C converts to Class 529-A after five years
Class 529-E	None	None	None
Classes T and 529-T*	Up to 2.50%	None	None
Classes F-1, F-2, F-3, 529-F-1, 529-F-2 and 529-F-3	None	None	None
Classes R-1, R-2, R-2E, R-3, R-4, R-5E, R-5 and R-6	None	None	None

*Class T and 529-T shares are not available for purchase.

Holders of all share classes have equal pro rata rights to the assets, dividends and liquidation proceeds of the fund. Each share class has identical voting rights, except for the exclusive right to vote on matters affecting only its class. Share classes have different fees and expenses ("class-specific fees and expenses"), primarily due to different arrangements for distribution, transfer agent and administrative services. Differences in class-specific fees and expenses will result in differences in net investment income and, therefore, the payment of different per-share dividends by each share class.

2. Significant accounting policies

The fund is an investment company that applies the accounting and reporting guidance issued in Topic 946 by the U.S. Financial Accounting Standards Board. The fund's financial statements have been prepared to comply with U.S. generally accepted accounting principles ("U.S. GAAP"). These principles require the fund's investment adviser to make estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates. Subsequent events, if any, have been evaluated through the date of issuance in the preparation of the financial statements. The fund follows the significant accounting policies described in this section, as well as the valuation policies described in the next section on valuation.

Security transactions and related investment income – Security transactions are recorded by the fund as of the date the trades are executed with brokers. Realized gains and losses from security transactions are determined based on the specific identified cost of the securities. In the event a security is purchased with a delayed payment date, the fund will segregate liquid assets sufficient to meet its payment obligations. Dividend income is recognized on the ex-dividend date and interest income is recognized on an accrual basis. Market discounts, premiums and original issue discounts on fixed-income securities are amortized daily over the expected life of the security.

Class allocations – Income, fees and expenses (other than class-specific fees and expenses), realized gains and losses and unrealized appreciation and depreciation are allocated daily among the various share classes based on their relative net assets. Class-specific fees and expenses, such as distribution, transfer agent and administrative services, are charged directly to the respective share class.

Distributions paid to shareholders – Income dividends and capital gain distributions are recorded on the ex-dividend date.

In-kind redemptions – The fund normally redeems shares in cash; however, under certain conditions and circumstances, payment of the redemption price wholly or partly with portfolio securities or other fund assets may be permitted. A redemption of shares in-kind is based upon the closing value of the shares being redeemed as of the trade date. Realized gains or losses resulting from redemptions of shares in-kind are reflected separately in the fund's statement of operations.

3. Valuation

Capital Research and Management Company ("CRMC"), the fund's investment adviser, values the fund's investments at fair value as defined by U.S. GAAP. The net asset value per share is calculated once daily as of the close of regular trading on the New York Stock Exchange, normally 4 p.m. New York time, each day the New York Stock Exchange is open.

Methods and inputs – The fund's investment adviser uses the following methods and inputs to establish the fair value of the fund's assets and liabilities. Use of particular methods and inputs may vary over time based on availability and relevance as market and economic conditions evolve.

Equity securities, including depositary receipts, are generally valued at the official closing price of, or the last reported sale price on, the exchange or market on which such securities are traded, as of the close of business on the day the securities are being valued or, lacking any sales, at the last available bid price. Prices for each security are taken from the principal exchange or market on which the security trades.

Fixed income securities, including short-term securities, are generally valued at evaluated prices obtained from third-party pricing vendors. Vendors value such securities based on one or more of the following inputs: benchmark yields, transactions, bids, offers, quotations from dealers and trading systems, new issues, spreads, interest rate volatilities, and other relationships observed in the markets among comparable securities; and proprietary pricing models such as yield measures calculated using factors such as cash flows, financial or collateral performance and other reference data.

Securities with both fixed-income and equity characteristics, or equity securities traded principally among fixed-income dealers, are generally valued in the manner described for either equity or fixed-income securities, depending on which method is deemed most appropriate by the fund's investment adviser. The Capital Group Central Cash Fund ("CCF"), a fund within the Capital Group Central Fund Series ("Central Funds"), is valued based upon a floating net asset value, which fluctuates with changes in the value of CCF's portfolio securities. The underlying securities are valued based on the policies and procedures in CCF's statement of additional information.

Securities and other assets for which representative market quotations are not readily available or are considered unreliable by the fund's investment adviser are fair valued as determined in good faith under fair valuation guidelines adopted by the fund's investment adviser and approved by the board of trustees as further described. The investment adviser follows fair valuation guidelines, consistent with U.S. Securities and Exchange Commission rules and guidance, to consider relevant principles and factors when making fair value determinations. The investment adviser considers relevant indications of value that are reasonably and timely available to it in determining the fair value to be assigned to a particular security, such as the type and cost of the security, contractual or legal restrictions on resale of the security, relevant financial or business developments of the issuer, actively traded similar or related securities, dealer or broker quotes, conversion or exchange rights on the security, related corporate actions, significant events occurring after the close of trading in the security, and changes in overall market conditions. In addition, the closing prices of equity securities that trade in markets outside U.S. time zones may be adjusted to reflect significant events that occur after the close of local trading but before the net asset value of each share class of the fund is determined. Fair valuations of investments that are not actively trading involve judgment and may differ materially from valuations that would have been used had greater market activity occurred.

Processes and structure – The fund's board of trustees has designated the fund's investment adviser to make fair value determinations, subject to board oversight. The investment adviser has established a Joint Fair Valuation Committee (the "Committee") to administer, implement and oversee the fair valuation process and to make fair value decisions. The Committee regularly reviews its own fair value decisions, as well as decisions made under its standing instructions to the investment adviser's valuation team. The Committee reviews changes in fair value measurements from period to period, pricing vendor information and market data, and may, as deemed appropriate, update the fair valuation guidelines to better reflect the results of back testing and address new or evolving issues. Pricing decisions, processes and controls over security valuation are also subject to additional internal reviews facilitated by the investment adviser's global risk management group. The Committee reports changes to the fair valuation guidelines to the trustees. The fund's board and audit committee also regularly review reports that describe fair value determinations and methods.

Classifications – The fund's investment adviser classifies the fund's assets and liabilities into three levels based on the inputs used to value the assets or liabilities. Level 1 values are based on quoted prices in active markets for identical securities. Level 2 values are based on significant observable market inputs, such as quoted prices for similar securities and quoted prices in inactive markets. Certain securities trading outside the U.S. may transfer between Level 1 and Level 2 due to valuation adjustments resulting from significant market movements following the close of local trading. Level 3 values are based on significant unobservable inputs that reflect the investment adviser's determination of assumptions that market participants might reasonably use in valuing the securities. The valuation levels are not necessarily an indication of the risk or liquidity associated with the underlying investment. For example, U.S. government securities are reflected as Level 2 because the inputs used to determine fair value may not always be quoted prices in an active market. As of October 31, 2024, all of the fund's investments were classifed as Level 1.

4. Risk factors

Investing in the fund may involve certain risks including, but not limited to, those described below.

Market conditions – The prices of, and the income generated by, the common stocks and other securities held by the fund may decline – sometimes rapidly or unpredictably – due to various factors, including events or conditions affecting the general economy or particular industries or companies; overall market changes; local, regional or global political, social or economic instability; governmental, governmental agency or central bank responses to economic conditions; changes in inflation rates; and currency exchange rate, interest rate and commodity price fluctuations.

Economies and financial markets throughout the world are highly interconnected. Economic, financial or political events, trading and tariff arrangements, wars, terrorism, cybersecurity events, natural disasters, public health emergencies (such as the spread of infectious disease), bank failures and other circumstances in one country or region, including actions taken by governmental or quasi-governmental authorities in response to any of the foregoing, could have impacts on global economies or markets. As a result, whether or not the fund invests in securities of issuers located in or with significant exposure to the countries affected, the value and liquidity of the fund's investments may be negatively affected by developments in other countries and regions.

Issuer risks – The prices of, and the income generated by, securities held by the fund may decline in response to various factors directly related to the issuers of such securities, including reduced demand for an issuer's goods or services, poor management performance, major litigation, investigations or other controversies related to the issuer, changes in the issuer's financial condition or credit rating, changes in government regulations affecting the issuer or its competitive environment and strategic initiatives such as mergers, acquisitions or dispositions and the market response to any such initiatives. An individual security may also be affected by factors relating to the industry or sector of the issuer or the securities markets as a whole, and conversely an industry or sector or the securities markets may be affected by a change in financial condition or other event affecting a single issuer.

Investing in income-oriented stocks – The value of the fund's securities and income provided by the fund may be reduced by changes in the dividend policies of, and the capital resources available for dividend payments at, the companies in which the fund invests.

Investing in growth-oriented stocks – Growth-oriented common stocks and other equity-type securities (such as preferred stocks, convertible preferred stocks and convertible bonds) may involve larger price swings and greater potential for loss than other types of investments.

Management – The investment adviser to the fund actively manages the fund's investments. Consequently, the fund is subject to the risk that the methods and analyses, including models, tools and data, employed by the investment adviser in this process may be flawed or incorrect and may not produce the desired results. This could cause the fund to lose value or its investment results to lag relevant benchmarks or other funds with similar objectives.

5. Certain investment techniques

Securities lending – The fund has entered into securities lending transactions in which the fund earns income by lending investment securities to brokers, dealers or other institutions. Each transaction involves three parties: the fund, acting as the lender of the securities, a borrower, and a lending agent that acts as an intermediary.

Securities lending transactions are entered into by the fund under a securities lending agent agreement with the lending agent. The lending agent facilitates the exchange of securities between the fund and approved borrowers, ensures that securities loans are properly coordinated and documented, marks-to-market the value of collateral daily, secures additional collateral from a borrower if it falls below preset terms, and may reinvest cash collateral on behalf of the fund according to agreed parameters. The lending agent provides indemnification to the fund against losses resulting from a borrower default. Although risk is mitigated by the collateral and indemnification, the fund could experience a delay in recovering its securities and a potential loss of income or value if a borrower fails to return securities, collateral investments decline in value or the lending agent fails to perform.

The borrower is required to post highly liquid assets, such as cash or U.S. government securities, as collateral for the loan in an amount at least equal to the value of the securities loaned. Investments made with cash collateral are recognized as assets in the fund's investment portfolio. The same amount is recorded as a liability in the fund's statement of assets and liabilities. While securities are on loan, the fund will continue to receive the equivalent of the interest, dividends or other distributions paid by the issuer, as well as a portion of the interest on the investment of the collateral. Additionally, although the fund does not have the right to vote on securities while they are on loan, the fund has a right to consent on corporate actions and a right to recall loaned securities to vote. A borrower is obligated to return loaned securities at the conclusion of a loan or, during the pendency of a loan, on demand from the fund.

As of October 31, 2024, the total value of securities on loan was \$262,170,000, and the total value of collateral received was \$268,084,000. Collateral received includes cash of \$242,413,000 and U.S. government securities of \$25,671,000. Investment securities purchased from cash collateral are disclosed in the fund's investment portfolio as short-term securities. Securities received as collateral are not recognized as fund assets. The contractual maturity of cash collateral received under the securities lending agreement is classified as overnight and continuous.

6. Taxation and distributions

Federal income taxation – The fund complies with the requirements under Subchapter M of the Internal Revenue Code applicable to regulated investment companies and intends to distribute substantially all of its net taxable income and net capital gains each year. The fund is not subject to income taxes to the extent such distributions are made. Therefore, no federal income tax provision is required.

As of and during the period ended October 31, 2024, the fund did not have a liability for any unrecognized tax benefits. The fund recognizes interest and penalties, if any, related to unrecognized tax benefits as income tax expense in the statement of operations. During the period, the fund did not incur any significant interest or penalties.

The fund's tax returns are generally not subject to examination by federal, state and, if applicable, non-U.S. tax authorities after the expiration of each jurisdiction's statute of limitations, which is typically three years after the date of filing but can be extended in certain jurisdictions.

Non-U.S. taxation – Dividend and interest income are recorded net of non-U.S. taxes paid. The fund may file withholding tax reclaims in certain jurisdictions to recover a portion of amounts previously withheld. As a result of rulings from European courts, the fund filed for additional reclaims related to prior years ("EU reclaims"). These reclaims are recorded when the amount is known and there are no significant uncertainties on collectability. During the six months ended October 31, 2024, the fund recognized \$1,066,000 in EU reclaims (net of \$15,000 in fees and the effect of realized gain or loss from currency translations) and \$28,000 in interest related to European court rulings, which is included in dividend income and interest income, respectively, in the fund's statement of operations. Gains realized by the fund on the sale of securities in certain countries, if any, may be subject to non-U.S. taxes. The fund generally records an estimated deferred tax liability based on unrealized gains to provide for potential non-U.S. taxes payable upon the sale of these securities.

Distributions – Distributions determined on a tax basis may differ from net investment income and net realized gains for financial reporting purposes. These differences are due primarily to different treatment for items such as currency gains and losses; short-term capital gains and losses; capital losses related to sales of certain securities within 30 days of purchase and cost of investments sold. The fiscal year in which amounts are distributed may differ from the year in which the net investment income and net realized gains are recorded by the fund for financial reporting purposes.

The components of distributable earnings on a tax basis are reported as of the fund's most recent year-end. As of April 30, 2024, the components of distributable earnings on a tax basis were as follows (dollars in thousands):

Undistributed ordinary income	\$ 400,411
Undistributed long-term capital gains	8,034,054

As of October 31, 2024, the tax basis unrealized appreciation (depreciation) and cost of investments were as follows (dollars in thousands):

Gross unrealized appreciation on investments	\$ 81.922.630
Gross unrealized depreciation on investments	(1,806,902)
Net unrealized appreciation (depreciation) on investments	80,115,728
Cost of investments	109,375,815

Distributions paid were characterized for tax purposes as follows (dollars in thousands):

	Six mon	ths ended October	31, 2024	024			
Share class	Ordinary income	Long-term capital gains	Total distributions paid	Ordinary income	Long-term capital gains	Total distributions paid	
Class A	\$ 558,608	\$3,725,157	\$4,283,765	\$1,289,727	\$3,415,650	\$ 4,705,377	
Class C	4,043	61,972	66,015	12,914	61,450	74,364	
Class T	_*	. 1	. 1	_*	. 1	. 1	
Class F-1	13,932	97,880	111,812	34,325	95,971	130,296	
Class F-2	254,482	1,479,384	1,733,866	565,839	1,336,514	1,902,353	
Class F-3	84,737	455,664	540,401	178,292	397,074	575,366	
Class 529-A	21,722	150,154	171,876	50,866	138,493	189,359	
Class 529-C	202	3,501	3,703	704	3,684	4,388	
Class 529-E	575	4,861	5,436	1,444	4,619	6,063	
Class 529-T	_*	1	1	_*	1	1	
Class 529-F-1	_*	1	1	_*	1	1	
Class 529-F-2	3,183	18,315	21,498	6,761	15,849	22,610	
Class 529-F-3	1	7	8	_*	1	1	
Class R-1	186	2,947	3,133	574	2,830	3,404	
Class R-2	2,174	34,588	36,762	6,823	32,541	39,364	
Class R-2E	484	5,167	5,651	1,244	4,622	5,866	
Class R-3	8,400	76,493	84,893	21,734	71,851	93,585	
Class R-4	16,636	116,059	132,695	41,487	114,114	155,601	
Class R-5E	3,817	22,338	26,155	10,148	24,368	34,516	
Class R-5	5,159	29,298	34,457	12,813	30,264	43,077	
Class R-6	320,464	1,751,219	2,071,683	701,854	1,570,015	2,271,869	
Total	\$1,298,805	\$8,035,007	\$9,333,812	\$2,937,549	\$7,319,913	\$10,257,462	

*Amount less than one thousand.

7. Fees and transactions with related parties

CRMC, the fund's investment adviser, is the parent company of Capital Client Group, Inc. ("CCG"), the principal underwriter of the fund's shares, and American Funds Service Company[®] ("AFS"), the fund's transfer agent. CRMC, CCG and AFS are considered related parties to the fund.

Investment advisory services – The fund has an investment advisory and service agreement with CRMC that provides for monthly fees accrued daily. These fees are based on a series of decreasing annual rates beginning with 0.342% on the first \$3 billion of daily net assets and decreasing to 0.2075% on such assets in excess of \$187 billion. For the six months ended October 31, 2024, the investment advisory services fees were \$207,585,000, which were equivalent to an annualized rate of 0.222% of average daily net assets.

Class-specific fees and expenses – Expenses that are specific to individual share classes are accrued directly to the respective share class. The principal class-specific fees and expenses are further described below:

Distribution services – The fund has plans of distribution for all share classes, except Class F-2, F-3, 529-F-2, 529-F-3, R-5E, R-5 and R-6 shares. Under the plans, the board of trustees approves certain categories of expenses that are used to finance activities primarily intended to sell fund shares and service existing accounts. The plans provide for payments, based on an annualized percentage of average daily net assets, ranging from 0.25% to 1.00% as noted in this section. In some cases, the board of trustees has limited the amounts that may be paid to less than the maximum allowed by the plans. All share classes with a plan may use up to 0.25% of average daily net assets to pay service fees, or to compensate CCG for paying service fees, to firms that have entered into agreements with CCG to provide certain shareholder services. The remaining amounts available to be paid under each plan are paid to dealers to compensate them for their sales activities.

Share class	Currently approved limits	Plan limit	
Class A	0.25%	0.25%	
Class 529-A	0.25	0.50	
Classes C, 529-C and R-1	1.00	1.00	
Class R-2	0.75	1.00	
Class R-2E	0.60	0.85	
Classes 529-E and R-3	0.50	0.75	
Classes T, F-1, 529-T, 529-F-1 and R-4	0.25	0.50	

For Class A and 529-A shares, distribution-related expenses include the reimbursement of dealer and wholesaler commissions paid by CCG for certain shares sold without a sales charge. These share classes reimburse CCG for amounts billed within the prior 15 months but only to the extent that the overall annual expense limits are not exceeded. As of October 31, 2024, there were no unreimbursed expenses subject to reimbursement for Class A or 529-A shares.

Transfer agent services – The fund has a shareholder services agreement with AFS under which the fund compensates AFS for providing transfer agent services to each of the fund's share classes. These services include recordkeeping, shareholder communications and transaction processing. Under this agreement, the fund also pays sub-transfer agency fees to AFS. These fees are paid by AFS to third parties for performing transfer agent services on behalf of fund shareholders.

Administrative services – The fund has an administrative services agreement with CRMC under which the fund compensates CRMC for providing administrative services to all share classes. Administrative services are provided by CRMC and its affiliates to help assist third parties providing non-distribution services to fund shareholders. These services include providing in-depth information on the fund and market developments that impact fund investments. Administrative services also include, but are not limited to, coordinating, monitoring and overseeing third parties that provide services to fund shareholders. The agreement provides the fund the ability to charge an administrative services fee at the annual rate of 0.05% of the average daily net assets attributable to each share class of the fund. Currently the fund pays CRMC an administrative services fee at the annual rate of 0.03% of the average daily net assets attributable to each share class of the fund for CRMC's provision of administrative services.

529 plan services – Each 529 share class is subject to service fees to compensate the Commonwealth Savers Plan (formerly, Virginia529) for its oversight and administration of the CollegeAmerica 529 college savings plan. The fees are based on the combined net assets invested in Class 529 and ABLE shares of the American Funds. Class ABLE shares are offered on other American Funds by Commonwealth Savers Plan through ABLEAmerica®, a tax-advantaged savings program for individuals with disabilities. Commonwealth Savers Plan is not considered a related party to the fund.

The quarterly fees are based on a series of decreasing annual rates beginning with 0.09% on the first \$20 billion of the combined net assets invested in the American Funds and decreasing to 0.03% on such assets in excess of \$75 billion. The fees for any given calendar quarter are accrued and calculated on the basis of the average net assets of Class 529 and ABLE shares of the American Funds for the last month of the prior calendar quarter. For the six months ended October 31, 2024, the 529 plan services fees were \$1,123,000, which were equivalent to 0.055% of the average daily net assets of each 529 share class.

For the six months ended October 31, 2024, class-specific expenses under the agreements were as follows (dollars in thousands):

Share class	Distribution services	Transfer agent services	Administrative services	529 plan services
Class A	\$104,771	\$23,988	\$12,984	Not applicable
Class C	6,953	387	211	Not applicable
Class T	_	_*	_*	Not applicable
Class F-1	2,796	1,333	340	Not applicable
Class F-2	Not applicable	18,928	5,167	Not applicable
Class F-3	Not applicable	61	1,611	Not applicable
Class 529-A	3,976	888	520	\$ 953
Class 529-C	386	21	12	22
Class 529-E	275	15	17	30
Class 529-T	_	_*	_*	_'
Class 529-F-1	_	_*	_*	_'
Class 529-F-2	Not applicable	77	64	118
Class 529-F-3	Not applicable	_*	_*	_*
Class R-1	332	29	10	Not applicable
Class R-2	2,930	1,310	117	Not applicable
Class R-2E	357	117	18	Not applicable
Class R-3	4,350	1,268	261	Not applicable
Class R-4	3,323	1,277	400	Not applicable
Class R-5E	Not applicable	404	81	Not applicable
Class R-5	Not applicable	167	101	Not applicable
Class R-6	Not applicable	229	6,097	Not applicable
Total class-specific expenses	\$130,449	\$50,499	\$28,011	\$1,123

*Amount less than one thousand.

Board members' deferred compensation – Board members who are unaffiliated with CRMC may elect to defer the cash payment of part or all of their compensation. These deferred amounts, which remain as liabilities of the fund, are treated as if invested in shares of the fund or other American Funds. These amounts represent general, unsecured liabilities of the fund and vary according to the total returns of the selected funds. Board members' compensation of \$1,971,000 in the fund's statement of operations reflects \$525,000 in current fees (either paid in cash or deferred) and a net increase of \$1,446,000 in the value of the deferred amounts.

Affiliated officers and trustees – Officers and certain trustees of the fund are or may be considered to be affiliated with CRMC, CCG and AFS. No affiliated officers or trustees received any compensation directly from the fund.

Investment in CCF – The fund holds shares of CCF, an institutional prime money market fund managed by CRMC. CCF invests in high-quality, short-term money market instruments. CCF is used as the primary investment vehicle for the fund's short-term instruments. CCF shares are only available for purchase by CRMC, its affiliates, and other funds managed by CRMC or its affiliates, and are not available to the public. CRMC does not receive an investment advisory services fee from CCF.

Security transactions with related funds – The fund purchased investment securities from, and sold investment securities to, other funds managed by CRMC (or funds managed by certain affiliates of CRMC) under procedures adopted by the fund's board of trustees. The funds involved in such transactions are considered related by virtue of having a common investment adviser (or affiliated investment advisers), common trustees and/or common officers. Each transaction was executed at the current market price of the security and no brokerage commissions or fees were paid in accordance with Rule 17a-7 of the 1940 Act. During the six months ended October 31, 2024, the fund engaged in such purchase and sale transactions with related funds in the amounts of \$844,300,000 and \$267,795,000, respectively, which generated \$29,227,000 of net realized gains from such sales.

Interfund lending – Pursuant to an exemptive order issued by the SEC, the fund, along with other CRMC-managed funds (or funds managed by certain affiliates of CRMC), may participate in an interfund lending program. The program provides an alternate credit facility that permits the funds to lend or borrow cash for temporary purposes directly to or from one another, subject to the conditions of the exemptive order. The fund did not lend or borrow cash through the interfund lending program at any time during the six months ended October 31, 2024.

8. Indemnifications

The fund's organizational documents provide board members and officers with indemnification against certain liabilities or expenses in connection with the performance of their duties to the fund. In the normal course of business, the fund may also enter into contracts that provide general indemnifications. The fund's maximum exposure under these arrangements is unknown since it is dependent on future claims that may be made against the fund. The risk of material loss from such claims is considered remote. Insurance policies are also available to the fund's board members and officers.

9. Capital share transactions

Capital share transactions in the fund were as follows (dollars and shares in thousands):

	Sales	,*	Reinvestm distribut		Repurcha	ises*	Net increase (decrease)		
Share class	Amount	Shares	Amount	Shares	Amount	Shares	Amount	Shares	
Six months ended Octo	ber 31, 2024								
Class A	\$1,807,337	29,040	\$4,205,506	70,062	\$ (4,642,513)	(74,722)	\$1,370,330	24,380	
Class C	81,313	1,331	65,625	1,115	(182,032)	(2,984)	(35,094)	(538	
Class T	-	_	_	_	_	_	_	_	
Class F-1	71,977	1,169	110,696	1,854	(160,869)	(2,607)	21,804	416	
Class F-2	2,910,134	46,967	1,699,247	28,344	(3,853,523)	(62,054)	755,858	13,257	
Class F-3	1,261,513	20,226	533,504	8,890	(980,755)	(15,804)	814,262	13,312	
Class 529-A	143,244	2,307	171,847	2,873	(267,047)	(4,319)	48,044	861	
Class 529-C	7,470	121	3,702	63	(17,162)	(279)	(5,990)	(95	
Class 529-E	5,843	95	5,435	92	(10,339)	(169)	939	18	
Class 529-T	_	_	1	_†	_	_	1	_	
Class 529-F-1	_	_	1	_†	_	_	1	_	
Class 529-F-2	35,970	578	21,495	358	(39,805)	(640)	17,660	296	
Class 529-F-3	23	1	8	_†	(69)	(1)	(38)	_	
Class R-1	3,429	56	3,132	53	(6,095)	(99)	466	10	
Class R-2	50,539	829	36,758	626	(91,489)	(1,500)	(4,192)	(45	
Class R-2E	9,903	162	5,651	95	(14,710)	(239)	844	18	
Class R-3	109,276	1,778	84,784	1,431	(212,060)	(3,453)	(18,000)	(244	
Class R-4	97,578	1,582	132,680	2,229	(266,953)	(4,333)	(36,695)	(522	
Class R-5E	60,766	986	26,151	436	(44,340)	(715)	42,577	707	
Class R-5	25,119	404	34,163	569	(86,523)	(1,394)	(27,241)	(421	
Class R-6	1,367,697	22,051	2,071,329	34,479	(2,512,710)	(40,472)	926,316	16,058	
Total net increase									
(decrease)	\$8,049,131	129,683	\$9,211,715	153,569	\$(13,388,994)	(215,784)	\$3,871,852	67,468	

	Sales	*	Reinvestm distribut		Repurcha	ases*	Net increase (decrease)	
ihare class	Amount	Shares	Amount	Shares	Amount	Shares	Amount	Shares
/ear ended April 30, 20)24							
Class A	\$ 3,665,274	65,121	\$ 4,615,092	83,465	\$ (8,129,220)	(144,910)	\$ 151,146	3,676
Class C	166,846	3,016	73,874	1,363	(370,783)	(6,706)	(130,063)	(2,327)
Class T	-	_	_	_	_	_	-	-
Class F-1	109,754	1,966	129,064	2,349	(441,124)	(7,978)	(202,306)	(3,663)
Class F-2	4,986,562	88,863	1,863,182	33,718	(5,937,917)	(106,023)	911,827	16,558
Class F-3	1,766,211	31,453	568,662	10,280	(1,772,662)	(31,582)	562,211	10,151
Class 529-A	273,594	4,879	189,283	3,435	(497,288)	(8,905)	(34,411)	(591)
Class 529-C	16,189	291	4,386	80	(35,263)	(636)	(14,688)	(265)
Class 529-E	7,418	134	6,062	111	(18,767)	(340)	(5,287)	(95
Class 529-T	_	_	1	_†	_	_	1	_
Class 529-F-1	-	_	1	_†	_	_	1	
Class 529-F-2	66,907	1,190	22,603	408	(63,302)	(1,130)	26,208	468
Class 529-F-3	130	2	1	_†	_	_	131	2
Class R-1	6,394	116	3,376	62	(15,302)	(280)	(5,532)	(102)
Class R-2	116,286	2,122	39,336	728	(175,588)	(3,195)	(19,966)	(345)
Class R-2E	19,210	343	5,866	107	(23,814)	(428)	1,262	22
Class R-3	213,728	3,855	93,480	1,712	(353,972)	(6,392)	(46,764)	(825
Class R-4	204,112	3,638	155,574	2,837	(583,273)	(10,490)	(223,587)	(4,015
Class R-5E	98,373	1,745	34,515	625	(225,601)	(3,841)	(92,713)	(1,471
Class R-5	59,677	1,059	42,729	775	(203,281)	(3,655)	(100,875)	(1,821
Class R-6	3,122,527	55,403	2,271,459	41,030	(4,615,918)	(82,803)	778,068	13,630
Total net increase								
(decrease)	\$14,899,192	265,196	\$10,118,546	183,085	\$(23,463,075)	(419,294)	\$1,554,663	28,987

*Includes exchanges between share classes of the fund.

[†]Amount less than one thousand.

10. Investment transactions

The fund engaged in purchases and sales of investment securities, excluding short-term securities and U.S. government obligations, if any, of \$21,752,273,000 and \$24,657,210,000, respectively, during the six months ended October 31, 2024.

Financial highlights

	9	9											
		Income (loss)) from investmer	nt operations ¹	Divid	lends and distri	butions						
Year ended	Net asset value, beginning of year	Net investment income (loss)	Net gains (losses) on securities (both realized and unrealized)	Total from investment operations	Dividends (from net investment income)	Distributions (from capital gains)	Total dividends and distributions	Net asset value, end of year	Total return ^{2,3}	Net assets, end of year (in millions)	Ratio of expenses to average net assets before reimburse- ments ⁴	Ratio of expenses to average net assets after reimburse- ments ^{3,4}	Ratio of net income (loss) to average net assets ³
Class A:													
10/31/2024 ^{5,6}	\$59.84	\$.45	\$ 6.51	\$ 6.96	\$ (.41)	\$(2.77)	\$(3.18)	\$63.62	11.97% ⁷	\$87,462	.56% ⁸	.56% ⁸	1.45% ⁸
4/30/2024	53.38	.95	9.02	9.97	(.96)	(2.55)	(3.51)	59.84	19.36	80,801	.57	.57	1.69
4/30/2023	55.52	1.00	.15	1.15	(1.02)	(2.27)	(3.29)	53.38	2.45	71,892	.57	.57	1.91
4/30/2022	56.35	.92	1.91	2.83	(.85)	(2.81)	(3.66)	55.52	4.98	72,922	.57	.57	1.59
4/30/2021	41.94	.83	15.12	15.95	(.87)	(.67)	(1.54)	56.35	38.63	71,469	.58	.58	1.73
4/30/2020	46.68	.88	(2.36)	(1.48)	(.88)	(2.38)	(3.26)	41.94	(3.63)	54,235	.58	.58	1.93
Class C:													
10/31/2024 ^{5,6}	58.75	.22	6.38	6.60	(.18)	(2.77)	(2.95)	62.40	11.55 ⁷	1,390	1.31 ⁸	1.31 ⁸	.70 ⁸
4/30/2024	52.48	.52	8.84	9.36	(.54)	(2.55)	(3.09)	58.75	18.43	1,340	1.32	1.32	.94
4/30/2023	54.62	.60	.15	.75	(.62)	(2.27)	(2.89)	52.48	1.71	1,319	1.32	1.32	1.16
4/30/2022	55.48	.48	1.89	2.37	(.42)	(2.81)	(3.23)	54.62	4.20	1,452	1.32	1.32	.84
4/30/2021	41.33	.47	14.87	15.34	(.52)	(.67)	(1.19)	55.48	37.56	1,509	1.33	1.33	.99
4/30/2020	46.01	.54	(2.31)	(1.77)	(.53)	(2.38)	(2.91)	41.33	(4.33)	1,497	1.33	1.33	1.19
Class T:													
10/31/2024 ^{5,6}	59.82	.53	6.52	7.05	(.49)	(2.77)	(3.26)	63.61	12.14 ^{7,9}	_1	^o .31 ^{8,9}	.31 ^{8,9}	1.69 ^{8,9}
4/30/2024	53.38	1.09	9.00	10.09	(1.10)	(2.55)	(3.65)	59.82	19.62 ⁹	_1		.329	1.94 ⁹
4/30/2023	55.51	1.14	.15	1.29	(1.10)	(2.33)	(3.42)	53.38	2.75 ⁹	_1		.32 .30 ⁹	2.17 ⁹
4/30/2022	56.34	1.06	1.92	2.98	(1.10)	(2.27)	(3.81)	55.51	5.25 ⁹	_1	.30° °.32°	.32%	1.84 ⁹
4/30/2021	41.93	.95	15.12	16.07	(1.00)	(.67)	(1.66)	56.34	38.96 ⁹	_1		.339	1.98 ⁹
4/30/2020	46.68	1.00	(2.38)	(1.38)	(.99)	(2.38)	(3.37)	41.93	(3.39) ⁹	_1	100	.349	2.18 ⁹
Class F-1:													
10/31/2024 ^{5,6}	59.53	.43	6.47	6.90	(.39)	(2.77)	(3.16)	63.27	11.92 ⁷	2,286	.63 ⁸	.63 ⁸	1.38 ⁸
4/30/2024	53.12	.91	8.97	9.88	(.92)	(2.55)	(3.47)	59.53	19.28	2,126	.63	.63	1.64
4/30/2023	55.26	.97	.15	1.12	(.99)	(2.27)	(3.26)	53.12	2.40	2,092	.63	.63	1.85
4/30/2022	56.10	.88	1.90	2.78	(.81)	(2.81)	(3.62)	55.26	4.91	2,216	.63	.63	1.52
4/30/2021	41.76	.80	15.05	15.85	(.84)	(.67)	(1.51)	56.10	38.53	2,422	.64	.64	1.68
4/30/2020	46.49	.85	(2.35)	(1.50)	(.85)	(2.38)	(3.23)	41.76	(3.68)	2,529	.64	.64	1.88
Class F-2:													
10/31/2024 ^{5,6}	59.76	.51	6.50	7.01	(.47)	(2.77)	(3.24)	63.53	12.08 ⁷	35,015	.37 ⁸	.37 ⁸	1.64 ⁸
4/30/2024	53.32	1.06	9.00	10.06	(1.07)	(2.55)	(3.62)	59.76	19.57	32,142	.37	.37	1.89
4/30/2023	55.46	1.10	.15	1.25	(1.12)	(2.27)	(3.39)	53.32	2.67	27,795	.37	.37	2.10
4/30/2022	56.29	1.03	1.92	2.95	(.97)	(2.81)	(3.78)	55.46	5.18	28,561	.37	.37	1.78
4/30/2021	41.89	.93	15.11	16.04	(.97)	(.67)	(1.64)	56.29	38.91	26,849	.37	.37	1.93
4/30/2020	46.64	.97	(2.37)	(1.40)	(.97)	(2.38)	(3.35)	41.89	(3.44)	18,175	.39	.39	2.13
Class F-3:													
10/31/2024 ^{5,6}	59.80	.55	6.50	7.05	(.50)	(2.77)	(3.27)	63.58	12.14 ⁷	11,231	.26 ⁸	.26 ⁸	1.74 ⁸
4/30/2024	53.35	1.12	9.01	10.13	(1.13)	(2.55)	(3.68)	59.80	19.71	9,767	.26	.26	2.00
4/30/2023	55.49	1.16	.15	1.31	(1.18)	(2.27)	(3.45)	53.35	2.77	8,172	.26	.26	2.21
4/30/2022	56.32	1.09	1.92	3.01	(1.03)	(2.81)	(3.84)	55.49	5.30	7,842	.26	.26	1.89
4/30/2021	41.91	.99	15.10	16.09	(1.01)	(.67)	(1.68)	56.32	39.07	6,969	.27	.27	2.03
4/30/2020	46.66	1.02	(2.37)	(1.35)	(1.02)	(2.38)	(3.40)	41.91	(3.33)	4,154	.27	.27	2.24
Class 529-A:													
10/31/2024 ^{5,6}	59.64	.44	6.50	6.94	(.40)	(2.77)	(3.17)	63.41	11.98 ⁷	3,499	.60 ⁸	.60 ⁸	1.41 ⁸
4/30/2024	53.22	.93	8.98	9.91	(.94)	(2.55)	(3.49)	59.64	19.29	3,240	.61	.61	1.66
4/30/2023	55.36	.98	.15	1.13	(1.00)	(2.27)	(3.27)	53.22	2.42	2,923	.61	.61	1.87
4/30/2022	56.20	.89	1.91	2.80	(.83)	(2.81)	(3.64)	55.36	4.94	2,952	.60	.60	1.55
4/30/2021	41.83	.81	15.08	15.89	(.85)	(.67)	(1.52)	56.20	38.58	2,887	.62	.62	1.69
4/30/2020	46.56	.86	(2.35)	(1.49)	(.86)	(2.38)	(3.24)	41.83	(3.66)	2,142	.63	.63	1.89

Financial highlights (continued) Income (loss) from investment operations¹ Dividends and distribut

		Income (loss)	from investmer	nt operations ¹	Divid	ends and distri	butions						
Year ended	Net asset value, beginning of year	Net investment income (loss)	Net gains (losses) on securities (both realized and unrealized)	Total from investment operations	Dividends (from net investment income)	Distributions (from capital gains)	Total dividends and distributions	Net asset value, end of year	Total return ^{2,3}	Net assets, end of year (in millions)	Ratio of expenses to average net assets before reimburse- ments ⁴	Ratio of expenses to average net assets after reimburse- ments ^{3,4}	Ratio of net income (loss) to average net assets ³
Class 529-C:													
10/31/2024 ^{5,6}	\$59.22	\$.21	\$ 6.44	\$ 6.65	\$ (.16)	\$(2.77)	\$(2.93)	\$62.94	11.55% ⁷	\$ 76	1.35% ⁸	1.35% ⁸	.66% ⁸
4/30/2024	52.87	.50	8.90	9.40	(.50)	(2.55)	(3.05)	59.22	18.37	77	1.37	1.37	.90
4/30/2023	54.99	.57	.16	.73	(.58)	(2.27)	(2.85)	52.87	1.64	83	1.38	1.38	1.10
4/30/2022	55.84	.45	1.90	2.35	(.39)	(2.81)	(3.20)	54.99	4.14	93	1.36	1.36	.79
4/30/2021	41.56	.48	14.96	15.44	(.49)	(.67)	(1.16)	55.84	37.57	109	1.35	1.35	1.02
4/30/2020	46.25	.53	(2.33)	(1.80)	(.51)	(2.38)	(2.89)	41.56	(4.38)	216	1.36	1.36	1.16
Class 529-E:													
10/31/2024 ^{5,6}	59.16	.36	6.43	6.79	(.32)	(2.77)	(3.09)	62.86	11.82 ⁷	112	.84 ⁸	.84 ⁸	1.17 ⁸
4/30/2024	52.82	.78	8.91	9.69	(.80)	(2.55)	(3.35)	59.16	19.01	105	.85	.85	1.41
4/30/2023	54.96	.84	.16	1.00	(.87)	(2.27)	(3.14)	52.82	2.17	98	.85	.85	1.62
4/30/2022	55.82	.75	1.89	2.64	(.69)	(2.81)	(3.50)	54.96	4.69	103	.85	.85	1.31
4/30/2021	41.56	.70	14.98	15.68	(.75)	(.67)	(1.42)	55.82	38.27	107	.85	.85	1.47
4/30/2020	46.27	.75	(2.33)	(1.58)	(.75)	(2.38)	(3.13)	41.56	(3.89)	88	.86	.86	1.66
Class 529-T:													
10/31/2024 ^{5,6}	59.83	.51	6.51	7.02	(.47)	(2.77)	(3.24)	63.61	12.07 ^{7,9}	_10	.37 ^{8,9}	.37 ^{8,9}	1.64 ^{8,9}
4/30/2024	53.38	1.06	9.01	10.07	(1.07)	(2.55)	(3.62)	59.83	19.569	_10	.37%	.379	1.889
4/30/2023	55.51	1.11	.16	1.27	(1.13)	(2.27)	(3.40)	53.38	2.69 ⁹	_10	.369	.369	2.11 ⁹
4/30/2022	56.34	1.03	1.91	2.94	(.96)	(2.81)	(3.77)	55.51	5.18 ⁹	_10	.389	.389	1.77 ⁹
4/30/2021	41.93	.93	15.11	16.04	(.96)	(.67)	(1.63)	56.34	38.90 ⁹	_10	.389	.389	1.92 ⁹
4/30/2020	46.68	.97	(2.37)	(1.40)	(.97)	(2.38)	(3.35)	41.93	(3.44) ⁹	_10	.389	.389	2.14 ⁹
Class 529-F-1:													
10/31/2024 ^{5,6}	59.40	.49	6.47	6.96	(.45)	(2.77)	(3.22)	63.14	12.07 ^{7,9}	_10	.44 ^{8,9}	.44 ^{8,9}	1.57 ^{8,9}
4/30/2024	53.02	1.02	8.94	9.96	(1.03)	(2.77)	(3.58)	59.40	12.07 19.49 ⁹	10	.44 .43 ⁹	.44 .43 ⁹	1.83 ⁹
4/30/2023	55.17	1.02	.15	1.21	(1.03)	(2.33)	(3.36)	53.02	2.59 ⁹		.43 .44 ⁹	.43 .44 ⁹	2.03 ⁹
4/30/2022	56.01	.99	1.90	2.89	(1.07)	(2.27)	(3.73)	55.17	5.13 ⁹	10	.44 .43 ⁹	.44 .43 ⁹	2.03 1.72 ⁹
4/30/2021	41.70	.84	15.10	15.94	(.72)		(1.63)	56.01	38.87 ⁹	10	.43 .40 ⁹	.43 .40 ⁹	1.72 1.88 ⁹
4/30/2020	41.70	.96	(2.35)	(1.39)	(.90)	(.67) (2.38)	(3.35)	41.70	(3.45)	 192	.40	.40	2.12
Class 529-F-2:													
10/31/2024 ^{5,6}	59.83	.52	6.50	7.02	(.47)	(2.77)	(3.24)	63.61	12.09 ⁷	438	.35 ⁸	.35 ⁸	1.65 ⁸
4/30/2024	53.38	1.07	9.01	10.08	(1.08)	(2.55)	(3.63)	59.83	19.59	395	.36	.36	1.90
4/30/2023	55.52	1.11	.15	1.26	(1.13)	(2.27)	(3.40)	53.38	2.71	327	.34	.34	2.13
4/30/2022	56.34	1.04	1.92	2.96	(.97)	(2.81)	(3.78)	55.52	5.19	303	.36	.36	1.79
4/30/2021 ^{5,11}	44.47	.50	12.55	13.05	(.51)	(.67)	(1.18)	56.34	29.66 ⁷	269	.38 ⁸	.38 ⁸	1.95 ⁸
Class 529-F-3:													
10/31/2024 ^{5,6}	59.82	.53	6.51	7.04	(.48)	(2.77)	(3.25)	63.61	12.13 ⁷	_10	.32 ⁸	.32 ⁸	1.70 ⁸
4/30/2024	53.37	.95	9.15	10.10	(1.10)	(2.55)	(3.65)	59.82	19.63	_10	.32	.32	1.66
4/30/2023	55.51	1.13	.15	1.28	(1.15)	(2.27)	(3.42)	53.37	2.72	10	.32	.32	2.15
4/30/2022	56.34	1.06	1.92	2.98	(1.00)	(2.81)	(3.81)	55.51	5.25	_10	.32	.32	1.84
4/30/2021 ^{5,11}	44.47	.51	12.55	13.06	(.52)	(.67)	(1.19)	56.34	29.69 ⁷	_10	.43 ⁸	.32 ⁸	2.01 ⁸
Class R-1:							· · · ·						
10/31/2024 ^{5,6}	58.96	.21	6.40	6.61	(.17)	(2.77)	(2.94)	62.63	11.53 ⁷	67	1.34 ⁸	1.34 ⁸	.67 ⁸
4/30/2024	52.66	.21	8.87	9.38	(.17)	(2.77)	(2.74)	58.96	18.40	63	1.34	1.34	.87
4/30/2023	54.79	.51	.16	.75	(.53)	(2.33)	(2.88)	52.66	1.68	61	1.33	1.33	1.14
4/30/2023	55.64	.37	1.90	2.36	(.40)	(2.27)	(3.21)	54.79	4.18	68	1.34	1.34	.80
4/30/2022	55.64 41.45	.40 .46	1.90	2.30 15.38			(3.21) (1.19)	55.64	37.53	00 75	1.35	1.35	.80
4/30/2020	41.45	.40 .52	(2.31)	(1.79)	(.52) (.51)	(.67) (2.38)	(1.19) (2.89)	55.64 41.45	(4.37)	67	1.35	1.35	.90 1.15
TI JUI LULU	+0.13	.JZ	(2.31)	(1.77)	()	(2.50)	(2.07)	71.43	(1.37)	07	1.57	1.57	1.15

Financial highlights (continued)

		Income (loss)	from investmer	nt operations ¹	Divid	ends and distri	butions						
Year ended	Net asset value, beginning of year	Net investment income (loss)	Net gains (losses) on securities (both realized and unrealized)	Total from investment operations	Dividends (from net investment income)	Distributions (from capital gains)	Total dividends and distributions	Net asset value, end of year	Total return ^{2,3}	Net assets, end of year (in millions)	Ratio of expenses to average net assets before reimburse- ments ⁴	Ratio of expenses to average net assets after reimburse- ments ^{3,4}	Ratio of net income (loss) to average net assets ³
Class R-2:													
10/31/2024 ^{5,6}	\$58.60	\$.20	\$ 6.37	\$ 6.57	\$ (.17)	\$(2.77)	\$(2.94)	\$62.23	11.53% ⁷	\$ 779	1.35% ⁸	1.35% ⁸	.66% ⁸
4/30/2024	52.36	.50	8.82	9.32	(.53)	(2.55)	(3.08)	58.60	18.40	736	1.35	1.35	.91
4/30/2023	54.51	.58	.15	.73	(.61)	(2.27)	(2.88)	52.36	1.67	675	1.36	1.36	1.12
4/30/2022	55.38	.45	1.89	2.34	(.40)	(2.81)	(3.21)	54.51	4.15	701	1.35	1.35	.80
4/30/2021	41.26	.45	14.85	15.30	(.51)	(.67)	(1.18)	55.38	37.54	739	1.37	1.37	.94
4/30/2020	45.94	.52	(2.31)	(1.79)	(.51)	(2.38)	(2.89)	41.26	(4.37)	611	1.37	1.37	1.15
Class R-2E:													
10/31/2024 ^{5,6}	59.44	.30	6.47	6.77	(.26)	(2.77)	(3.03)	63.18	11.71 ⁷	119	1.06 ⁸	1.06 ⁸	.95 ⁸
4/30/2024	53.06	.67	8.95	9.62	(.69)	(2.55)	(3.24)	59.44	18.74	110	1.06	1.06	1.20
4/30/2023	55.19	.74	.16	.90	(.76)	(2.27)	(3.03)	53.06	1.97	98	1.06	1.06	1.41
4/30/2022	56.03	.63	1.90	2.53	(.56)	(2.81)	(3.37)	55.19	4.47	95	1.06	1.06	1.09
4/30/2021	41.72	.59	15.03	15.62	(.64)	(.67)	(1.31)	56.03	37.92	98	1.08	1.08	1.24
4/30/2020	46.43	.66	(2.34)	(1.68)	(.65)	(2.38)	(3.03)	41.72	(4.09)	92	1.07	1.07	1.45
Class R-3:													
10/31/2024 ^{5,6}	59.12	.34	6.43	6.77	(.30)	(2.77)	(3.07)	62.82	11.79 ⁷	1,730	.91 ⁸	.91 ⁸	1.10 ⁸
4/30/2024	52.79	.75	8.90	9.65	(.77)	(2.55)	(3.32)	59.12	18.93	1,642	.91	.91	1.35
4/30/2023	54.93	.81	.15	.96	(.83)	(2.27)	(3.10)	52.79	2.11	1,510	.91	.91	1.56
4/30/2022	55.78	.71	1.90	2.61	(.65)	(2.81)	(3.46)	54.93	4.64	1,663	.91	.91	1.24
4/30/2021	41.54	.66	14.96	15.62	(.71)	(.67)	(1.38)	55.78	38.13	1,904	.92	.92	1.39
4/30/2020	46.24	.72	(2.32)	(1.60)	(.72)	(2.38)	(3.10)	41.54	(3.94)	1,604	.92	.92	1.60
Class R-4:													
10/31/2024 ^{5,6}	59.39	.44	6.45	6.89	(.39)	(2.77)	(3.16)	63.12	11.96 ⁷	2,652	.61 ⁸	.61 ⁸	1.40 ⁸
4/30/2024	53.01	.92	8.95	9.87	(.94)	(2.55)	(3.49)	59.39	19.29	2,526	.61	.61	1.66
4/30/2023	55.15	.97	.15	1.12	(.99)	(2.27)	(3.26)	53.01	2.42	2,468	.61	.61	1.87
4/30/2022	55.99	.89	1.90	2.79	(.82)	(2.81)	(3.63)	55.15	4.94	2,738	.61	.61	1.54
4/30/2021	41.68	.81	15.02	15.83	(.85)	(.67)	(1.52)	55.99	38.57	3,322	.62	.62	1.69
4/30/2020	46.41	.86	(2.35)	(1.49)	(.86)	(2.38)	(3.24)	41.68	(3.67)	2,874	.62	.62	1.90
Class R-5E:													
10/31/2024 ^{5,6}	59.70	.50	6.49	6.99	(.45)	(2.77)	(3.22)	63.47	12.07 ⁷	557	.41 ⁸	.41 ⁸	1.59 ⁸
4/30/2024	53.27	1.04	8.99	10.03	(1.05)	(2.55)	(3.60)	59.70	19.52	482	.41	.41	1.86
4/30/2023	55.41	1.08	.15	1.23	(1.10)	(2.27)	(3.37)	53.27	2.61	508	.41	.41	2.06
4/30/2022	56.25	1.00	1.91	2.91	(.94)	(2.81)	(3.75)	55.41	5.14	485	.41	.41	1.74
4/30/2021	41.86	.92	15.09	16.01	(.95)	(.67)	(1.62)	56.25	38.88	536	.41	.41	1.89
4/30/2020	46.61	.95	(2.35)	(1.40)	(.97)	(2.38)	(3.35)	41.86	(3.45)	292	.41	.41	2.11
Class R-5:													
10/31/2024 ^{5,6}	59.80	.53	6.52	7.05	(.49)	(2.77)	(3.26)	63.59	12.13 ⁷	663	.31 ⁸	.31 ⁸	1.70 ⁸
4/30/2024	53.36	1.09	9.00	10.09	(1.10)	(2.55)	(3.65)	59.80	19.62	648	.31	.31	1.95
4/30/2023	55.49	1.14	.15	1.29	(1.15)	(2.27)	(3.42)	53.36	2.73	676	.31	.31	2.17
4/30/2022	56.32	1.06	1.92	2.98	(1.00)	(2.81)	(3.81)	55.49	5.25	815	.31	.31	1.84
4/30/2021	41.91	.96	15.11	16.07	(.99)	(.67)	(1.66)	56.32	39.00	1,005	.32	.32	2.00
4/30/2020	46.66	1.01	(2.38)	(1.37)	(1.00)	(2.38)	(3.38)	41.91	(3.38)	996	.32	.32	2.20
Class R-6:													
10/31/2024 ^{5,6}	59.87	.55	6.51	7.06	(.50)	(2.77)	(3.27)	63.66	12.17 ⁷	41,147	.26 ⁸	.26 ⁸	1.74 ⁸
4/30/2024	53.41	1.12	9.02	10.14	(1.13)	(2.55)	(3.68)	59.87	19.70	37,736	.26	.26	2.00
4/30/2023	55.55	1.16	.15	1.31	(1.18)	(2.27)	(3.45)	53.41	2.76	32,937	.26	.26	2.21
4/30/2022	56.38	1.09	1.92	3.01	(1.03)	(2.81)	(3.84)	55.55	5.30	32,755	.26	.26	1.89
4/30/2021	41.96	.99	15.12	16.11	(1.02)	(.67)	(1.69)	56.38	39.04	32,128	.27	.27	2.04
4/30/2020	41.70	.//	(2.37)	(1.34)	(1.02)	(2.38)	(1.07)	50.50	(3.32)	23,486	.27	.27	2.25

Financial highlights (continued)

	Six months ended October 31,	Year ended April 30,								
	2024 ^{5,6,7}	2024	2023	2022	2021	2020				
Portfolio turnover rate for all share classes ¹²	12%	31%	30%	19%	24%	30%				

¹Based on average shares outstanding.

²Total returns exclude any applicable sales charges, including contingent deferred sales charges.

³This column reflects the impact, if any, of certain reimbursements from CRMC. During one of the years shown, CRMC reimbursed a portion of transfer agent services fees for Class 529-F-3 shares.

⁴Ratios do not include expenses of any Central Funds. The fund indirectly bears its proportionate share of the expenses of any Central Funds.

⁵Based on operations for a period that is less than a full year.

⁶Unaudited.

⁷Not annualized.

⁸Annualized.

⁹All or a significant portion of assets in this class consisted of seed capital invested by CRMC and/or its affiliates. Fees for distribution services are not charged or accrued on these seed capital assets. If such fees were paid by the fund on seed capital assets, fund expenses would have been higher and net income and total return would have been lower.

 $^{\rm 10}{\rm Amount}$ less than \$1 million.

¹¹Class 529-F-2 and 529-F-3 shares began investment operations on October 30, 2020.

¹²Rates do not include the fund's portfolio activity with respect to any Central Funds.

Not applicable

Matters submitted for shareholder vote

Not applicable

Remuneration paid to directors, officers and others

Refer to information in the financial statements.

Approval of Investment Advisory and Service Agreement

Not applicable